<SEC-DOCUMENT>0001213900-26-039529.txt : 20260402
<SEC-HEADER>0001213900-26-039529.hdr.sgml : 20260402
<ACCEPTANCE-DATETIME>20260402172509
ACCESSION NUMBER:		0001213900-26-039529
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20260331
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260402
DATE AS OF CHANGE:		20260402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42195
		FILM NUMBER:		26835553

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0284488-8k_ostherapies.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:OSTX="http://ostherapies.com/20260331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_OSTX_ostherapies.com_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20260331_20260331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001795091 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000004" name="dei:EntityCentralIndexKey">0001795091</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ostx-20260331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001795091</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-03-31</xbrli:startDate>
        <xbrli:endDate>2026-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20260331__20260331_zWsEhhpsUozl"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span style="text-decoration: underline"><span id="xdx_900_edei--DocumentPeriodEndDate_c20260331__20260331_znB4FzFlGW1d"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 31, 2026</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityRegistrantName_c20260331__20260331_zeDSxbU5RIHj"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000011" name="dei:EntityRegistrantName">OS THERAPIES INCORPORATED</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20260331__20260331_zU67XJPUPdce"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityFileNumber_c20260331__20260331_zbh9J1RGgj24"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000013" name="dei:EntityFileNumber">001-42195</ix:nonNumeric></span></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20260331__20260331_zsE4MmZCRhL1"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000014" name="dei:EntityTaxIdentificationNumber">82-5118368</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction<br/>
    of incorporation)</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer<br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityAddressAddressLine1_c20260331__20260331_zYtRSQxqBPF"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000015" name="dei:EntityAddressAddressLine1">115  Pullman Crossing Road</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20260331__20260331_zK7ikJ20Rdob"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 103</ix:nonNumeric></span><br/>
    <span id="xdx_909_edei--EntityAddressCityOrTown_c20260331__20260331_zfnhu88pNDL2"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000017" name="dei:EntityAddressCityOrTown">Grasonville</ix:nonNumeric></span>, <span id="xdx_90A_edei--EntityAddressStateOrProvince_c20260331__20260331_ziQAAID0jA7"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Maryland</ix:nonNumeric></span></span></td>
    <td style="vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20260331__20260331_zRg3rGQorSt8"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000019" name="dei:EntityAddressPostalZipCode">21638</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span style="text-decoration: underline">(<span id="xdx_90F_edei--CityAreaCode_c20260331__20260331_zv99J6Zu1gjj"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000020" name="dei:CityAreaCode">410</ix:nonNumeric></span>)</span> <span id="xdx_909_edei--LocalPhoneNumber_c20260331__20260331_zsUyVKEMLJGf"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000021" name="dei:LocalPhoneNumber">297-7793</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (<i>see </i>General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20260331__20260331_z0n8AQJXQgBe"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20260331__20260331_zswyj85cooS"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20260331__20260331_ziX8fyXqyMe"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20260331__20260331_zZjzBOZvwPC8"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of Each Class</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Each Exchange on Which Registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20260331__20260331_z9JzHZgIL2M8"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000026" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20260331__20260331_zQkbV0fla90b"><ix:nonNumeric contextRef="AsOf2026-03-31" id="Fact000027" name="dei:TradingSymbol">OSTX</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SecurityExchangeName_c20260331__20260331_z1mbjTuAlav8"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20260331__20260331_zJVMbyxgsDTe"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleantrue" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_906_edei--EntityExTransitionPeriod_c20260331__20260331_z4gdzRtimmnj"><ix:nonNumeric contextRef="AsOf2026-03-31" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT ON FORM 8-K</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OS
Therapies Incorporated</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31, 2026</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01. Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Securities
Purchase Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 31, 2026, OS Therapies
Incorporated (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with the
purchasers identified on the signature pages thereto (the &#8220;Purchasers&#8221;), pursuant to which the Company offered for sale to
the Purchasers in a registered direct offering (the &#8220;Offering&#8221;) an aggregate of 2,505,073 shares of its common stock and,
in lieu thereof, pre-funded warrants to purchase up to 1,250,893 shares of its common stock (the &#8220;pre-funded warrants&#8221;), and
accompanying warrants to purchase up to 3,755,966 shares of its common stock (the &#8220;common warrants&#8221;). The shares of common
stock, pre-funded warrants and common warrants (including the shares of common stock underlying the pre-funded warrants and common warrants)
were offered by the Company pursuant to the Company&#8217;s shelf registration statement on Form S-3 (File No. 333-289443) filed by the
Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;) on August 8, 2025 and declared effective by the
Commission on August 12, 2025 (the &#8220;Registration Statement&#8221;), and the prospectus supplement dated March 31, 2026 filed by
the Company with the Commission on April 2, 2026 (the &#8220;Prospectus Supplement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The combined purchase price
for each share and common warrant in the Offering was $1.40, and the purchase price for each pre-funded warrant and common warrant in
the Offering was $1.399, which is equal to the per share and common warrant purchase price, minus $0.001. The closing of the Offering
occurred on April 2, 2026. The Company received net&#160;proceeds from the Offering of approximately $4.7 million. The Company intends
to use the net proceeds to fund clinical development activities, including ongoing and planned clinical trials, advance its research and
development programs, and acquire or invest in technologies, product candidates or businesses that are complementary to its strategic
objectives, as well as for working capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Agreement contains
customary representations, warranties and agreements by the Company, indemnification obligations of the Company and the Purchasers, including
for liabilities arising under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Purchase Agreement,
the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common
stock or any securities convertible into or exercisable or exchangeable for shares of common stock or file any registration statement
or prospectus, or any amendment or supplement thereto, for 90 days after the closing date of the Offering, subject to certain exceptions.
The Company also agreed not to effect or enter into an agreement to effect any issuance of common stock or any securities convertible
into or exercisable or exchangeable for shares of common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement)
until 180 days after the closing date of the Offering.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Placement
Agent Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Offering, on March 31, 2026, the Company entered into a placement agency agreement (the &#8220;Placement Agent Agreement&#8221;)
with Ceros Financial Services, Inc. (the &#8220;Placement Agent&#8221;), pursuant to which the Placement Agent agreed to act as the Company&#8217;s
exclusive placement agent in connection with the Offering. The Company agreed to pay the Placement Agent a cash fee equal to 7.0% of
the gross proceeds raised in the Offering. The Company also agreed to reimburse the Placement Agent up to $70,000 for its reasonable
and documented out-of-pocket accountable expenses and up to $20,000 for its non-accountable expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company also issued to
the Placement Agent, or its designees, warrants (the &#8220;placement agent warrants&#8221;) to purchase up to 187,798 shares of the Company&#8217;s
common stock (equal to 5.0% of the aggregate number of shares of common stock and pre-funded warrants sold in the Offering). The placement
agent warrants have an exercise price of $1.54 per share (which represents 110% of the offering price per share and accompanying common
warrant), are exercisable beginning six months after the date of issuance and expire five years from April 2, 2026.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the shares of common stock, the pre-funded warrants and the common warrants (including the shares of common stock underlying
the pre-funded warrants and common warrants), the placement agent warrants and the shares of common stock underlying the placement agent
warrants were offered by the Company pursuant to the Registration Statement and the Prospectus Supplement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Placement Agent Agreement contains customary representations, warranties, and agreements by the Company, indemnification obligations
of the Company, other obligations of the parties and termination provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of the Pre-Funded Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the pre-funded warrants is not complete and is subject to, and qualified in its
entirety by, the provisions of the pre-funded warrants, the form of which is filed as Exhibit 4.1 to this Current Report on Form 8-K
and incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Duration and Exercise
Price</i></b>. Each pre-funded warrant is exercisable at any time beginning on the date of issuance and expires only when fully exercised.
Each pre-funded warrant entitles the holder thereof to purchase shares of the Company&#8217;s common stock at an exercise price equal
to $0.001 per share. The exercise price and number of shares of the Company&#8217;s common stock issuable upon exercise of each pre-funded
warrant is subject to adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#8217;s
common stock and the exercise price.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisability</i></b>.
The holder of the pre-funded warrant may exercise the pre-funded warrant by delivering an exercise notice, completed and duly signed,
and payment in cash of the exercise price for the number of shares of the Company&#8217;s common stock for which the pre-funded warrant
is being exercised. The holder of the pre-funded warrant may also satisfy its obligation to pay the exercise price through a &#8220;cashless
exercise,&#8221; in which the holder receives the net value of the pre-funded warrant in shares of common stock determined according
to the formula set forth in the pre-funded warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the pre-funded warrant will not be entitled to exercise any portion of such pre-funded warrant that, upon giving effect to
such exercise, would cause the aggregate number of shares of the Company&#8217;s common stock beneficially owned by such holder (together
with its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes
of Section&#160;13(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) to exceed 4.99% (or, at the
holder&#8217;s election, 9.99%) of the total number of then issued and outstanding shares of the Company&#8217;s common stock, as such&#160;percentage
ownership is determined in accordance with the terms of the pre-funded warrant and subject to such holder&#8217;s rights under the pre-funded
warrant to increase or decrease such&#160;percentage to any other&#160;percentage not in excess of 19.99% upon at least 61&#160;days&#8217;
prior notice from such holder to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fundamental
Transaction</i></b>. In the event of any fundamental transaction, as described in the pre-funded warrants and generally including any
merger with or into another entity, sale of all or substantially all of the Company&#8217;s assets, tender offer or exchange offer, or
reclassification of the Company&#8217;s shares of common stock, then upon any subsequent exercise of a pre-funded warrant, the holder
will have the right to receive as alternative consideration, for each share of common stock that would have been issuable upon such exercise
immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring
corporation of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such
transaction by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transferability</i></b>.
Subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant
to the Company together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
Listing</i></b>. There is no established public trading market available for the pre-funded warrants on any securities exchange or nationally
recognized trading system. The Company does not intend to list the pre-funded warrants on the NYSE American or any other securities exchange
or nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will initially serve as the warrant agent for the pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right
as a Stockholder</i></b><i>. </i>Except as otherwise provided in the pre-funded warrants or by virtue of such holder&#8217;s ownership
of shares of the Company&#8217;s common stock, the holders of the pre-funded warrants do not have the rights or privileges of holders
of the Company&#8217;s common stock, including any voting rights, until they exercise their pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Terms
of the Common Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the common warrants is not complete and is subject to, and qualified in its entirety
by, the provisions of the common warrants, the form of which is filed as Exhibit 4.2 to this Current Report on Form 8-K and incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Duration and Exercise
Price. </i></b>Each common warrant is immediately exercisable upon issuance and expires five years from the date of issuance. Each common
warrant entitles the holder thereof to purchase shares of the Company&#8217;s common stock at an exercise price equal to $1.40 per share.
The exercise price and number of shares of the Company&#8217;s common stock issuable upon exercise of each common warrant is subject to
adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the Company&#8217;s common stock
and the exercise price.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exercisability.
</i></b>The holder of the common warrant may exercise the common warrant by delivering an exercise notice, completed and duly signed,
and payment in cash of the exercise price for the number of shares of the Company&#8217;s common stock for which the common warrant is
being exercised. The holder of the common warrant may also satisfy its obligation to pay the exercise price through a &#8220;cashless
exercise,&#8221; in which the holder receives the net value of the common warrant in shares of common stock determined according to the
formula set forth in the common warrant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of the common warrant will not be entitled to exercise any portion of such common warrant that, upon giving effect to such exercise,
would cause the aggregate number of shares of the Company&#8217;s common stock beneficially owned by such holder (together with its affiliates
and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes of Section 13(d) of
the Exchange Act) to exceed 4.99% (or, at the holder&#8217;s election, 9.99%) of the total number of then issued and outstanding shares
of the Company&#8217;s common stock, as such percentage ownership is determined in accordance with the terms of the common warrant and
subject to such holder&#8217;s rights under the common warrant to increase or decrease such percentage to any other percentage not in
excess of 19.99% upon at least 61 days&#8217; prior notice from such holder to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fundamental
Transactions. </i></b>In the event of any fundamental transaction, as described in the common warrants and generally including any merger
with or into another entity, sale of all or substantially all of the Company&#8217;s assets, tender offer or exchange offer, or reclassification
of the Company&#8217;s shares of common stock, then upon any subsequent exercise of a common warrant, the holder will have the right
to receive as alternative consideration, for each share of common stock that would have been issuable upon such exercise immediately
prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation
of the Company, if it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction
by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transferability.
</i></b>Subject to applicable laws, a common warrant may be transferred at the option of the holder upon surrender of the common warrant
to the Company together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exchange
Listing. </i></b>There is no established public trading market available for the common warrants on any securities exchange or nationally
recognized trading system. The Company does not intend to list the common warrants on the NYSE American or any other securities exchange
or nationally recognized trading system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will initially serve as the warrant agent for the common warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Right
as a Stockholder. </i></b>Except as otherwise provided in the common warrants or by virtue of such holder&#8217;s ownership of shares
of the Company&#8217;s common stock, the holders of the common warrants do not have the rights or privileges of holders of the Company&#8217;s
common stock, including any voting rights, until they exercise their common warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the Placement Agent Agreement, the pre-funded warrants, the common warrants, the placement agent warrants and
the Purchase Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Placement
Agent Agreement and the forms of pre-funded warrant, common warrant, placement agent warrant and Purchase Agreement, copies of which
are filed as Exhibits 1.1, 4.1, 4.2, 4.3 and 10.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations, warranties and covenants contained in the Purchase Agreement and the Placement Agent Agreement were made only for purposes
of each such agreement and as of specific dates, were solely for the benefit of the parties thereto and may be subject to limitations
agreed upon by the contracting parties. Accordingly, the Purchase Agreement and the Placement Agent Agreement are incorporated herein
by reference only to provide investors with information regarding the terms of the Purchase Agreement and the Placement Agent Agreement
and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction
with the disclosures in the Company&#8217;s periodic reports and other filings with the Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion, including the related consent, of Olshan Frome Wolosky LLP relating to the issuance and sale of the Company&#8217;s securities
in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Current Report on Form 8-K does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale
of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2026, the Company issued a press release announcing the
closing of the Offering, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Forward-Looking
Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form
8-K, including Exhibit 99.1 hereto, contains forward-looking statements that involve risks and uncertainties, such as statements related
to the intended use of the net proceeds from the Offering. The risks and uncertainties involved include the Company&#8217;s financial
position, market conditions and other risks detailed from time to time in the Company&#8217;s periodic reports and other filings with
the Commission. You are cautioned not to place undue reliance on forward-looking statements, which are based on the Company&#8217;s current
expectations and assumptions and speak only as of the date of this Current Report on Form 8-K. The Company does not intend to revise or
update any forward-looking statement in this Current Report on Form 8-K as a result of new information, future events or otherwise, except
as required by U.S. federal securities law.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(d)
Exhibits.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<br/>
    Number </span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    </span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex1-1.htm">Placement Agency Agreement, dated as of March 31, 2026, by and between OS Therapies Incorporated and Ceros Financial Services, Inc.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex4-1.htm">Form of Pre-Funded Warrant.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex4-2.htm">Form of Common Warrant.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex4-3.htm">Form of Placement Agent Warrant.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex5-1.htm">Opinion of Olshan Frome Wolosky LLP.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex10-1.htm">Form of Securities Purchase Agreement.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea028448801ex5-1.htm">Consent of Olshan Frome Wolosky LLP (included in Exhibit 5.1).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>99.1</td>
    <td>&#160;</td>
    <td><a href="ea028448801ex99-1.htm">Press Release issued by OS Therapies Incorporated on April 2, 2026.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
                                            to Item&#160;601(a)(5)&#160;of Regulation&#160;S-K, certain schedules and exhibits have been
                                            omitted. The registrant agrees to furnish supplementally a copy of any omitted schedule or
                                            exhibit to the Commission upon its request.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OS THERAPIES INCORPORATED</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 2, 2026</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul A. Romness, MPH</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="width: 31%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul A. Romness, MPH</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6PLSbqLBHxxRxigwRX4vLpLg1I61zfpJ/ad0QQyAk955cIUKxobWukeGyKnI4YdPWyiEUWCGjuaJ3pNtdAn4WeNPWsTJuWH9gSp5Bzywmc+Xvg7PTFssE5Gw6i6bxAuQykRKOexF89ZRMpUs0TqsalCnhyNSyRqf4NX44qZ4MNa8h6YxsNZkEookc5TfEMorhQJ16Et8t5HkqgnCoQGyYHq13Zb1D8yUhq7HxcXak/x18AMqDSlo= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea028448801ex1-1.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT, DATED AS OF MARCH 31, 2026, BY AND BETWEEN OS THERAPIES INCORPORATED AND CEROS FINANCIAL SERVICES, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Ceros
Financial Services, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1445
Research Boulevard</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
MD 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OS
Therapies Incorporated<BR>
Attn: Paul A. Romness, MPH, President and Chief Executive Officer<BR>
115 Pullman Crossing Road, Suite #103<BR>
Grasonville, Maryland 21638</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter (the &ldquo;<B>Agreement</B>&rdquo;) constitutes the agreement between Ceros Financial Services, Inc. (the &ldquo;<B>Placement
Agent</B>&rdquo;) and OS Therapies Incorporated, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), that the Placement Agent
shall serve as the exclusive placement agent for the Company, on a reasonable &ldquo;best efforts&rdquo; basis, in connection with the
proposed placement (the &ldquo;<B>Placement</B>&rdquo;) of (i) shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s common
stock, par value $0.001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), (ii) pre-funded warrants to purchase shares of Common Stock
(the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;), and (iii) common warrants to purchase shares of Common Stock (the &ldquo;<B>Common Warrants</B>&rdquo;
and, collectively with the Pre-Funded Warrants, the &ldquo;<B>Warrants</B>&rdquo; and, together with the Shares, the &ldquo;<B>Securities</B>&rdquo;).
The Securities actually placed by the Placement Agent are referred to herein as the &ldquo;<B>Placement Agent Securities</B>.&rdquo;
The Placement Agent Securities shall be offered and sold pursuant to an effective registration statement on Form S-3 (File No. 333-289443)
(the &ldquo;Registration Statement&rdquo;) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder
(the &ldquo;<B>Securities Act</B>&rdquo;). The terms of the Placement shall be mutually agreed upon by the Company and the purchasers
(each, a &ldquo;<B>Purchaser</B>&rdquo; and collectively, the &ldquo;<B>Purchasers</B>&rdquo;), and nothing herein constitutes that the
Placement Agent would have the power or authority to bind the Company or any Purchaser, or an obligation for the Company to issue any
securities or complete the Placement. The Company expressly acknowledges and agrees that the Placement Agent&rsquo;s obligations hereunder
are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by the Placement
Agent to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success
of the Placement Agent with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other brokers
or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement; provided, however, that the Company
shall first approve any such sub-agents. Certain affiliates of the Placement Agent may participate in the Placement by purchasing some
of the Placement Agent Securities. The sale of Placement Agent Securities to the Purchasers will be evidenced by a securities purchase
agreement (the &ldquo;<B>Purchase Agreement</B>&rdquo;) between the Company and such Purchasers, in a form reasonably acceptable to the
Company and the Purchasers. Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase
Agreement. Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from the prospective
Purchasers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            and Warranties of the Company; Covenants of the Company</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            of the Company</U>. With respect to the Placement Agent Securities, each of the representations
                                            and warranties (together with any related disclosure schedules thereto) and covenants made
                                            by the Company to the Purchasers in the Purchase Agreement in connection with the Placement,
                                            are hereby incorporated herein by reference into this Agreement (as though fully restated
                                            herein) and is, as of the date of this Agreement and as of the date of the sale of the Placement
                                            Agent Securities (the &ldquo;<B>Closing Date</B>&rdquo;), hereby made to, and in favor of,
                                            the Placement Agent and shall be deemed to have been made directly to the Placement Agent
                                            as if set forth herein in full, <I>mutatis mutandis</I>, and the Placement Agent shall be
                                            entitled to rely thereon to the same extent as the Purchasers. The Company has full right,
                                            power and authority to enter into this Agreement and to perform its obligations hereunder.
                                            The execution, delivery and performance of this Agreement and the consummation of the transactions
                                            contemplated hereby do not and will not conflict with or result in a breach of any agreement
                                            to which the Company is a party, including any agreement with any other placement agent,
                                            underwriter or financial advisor. In addition to the foregoing, the Company represents and
                                            warrants that there are no affiliations with any Financial Industry Regulatory Authority
                                            (&ldquo;<B>FINRA</B>&rdquo;) member firm among the Company&rsquo;s officers, directors or,
                                            to the knowledge of the Company, any five percent (5.0%) or greater securityholder of the
                                            Company, except as set forth in the Purchase Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Covenants
                                            of the Company</U>. The Company covenants and agrees to continue to retain (i)&nbsp;an independent
                                            public accounting firm registered with the Public Company Accounting Oversight Board (the
                                            &ldquo;<B>PCAOB</B>&rdquo;) for a period of at least three (3) years after the Closing Date
                                            for so long as the Company has securities registered under the Exchange Act, and (ii) a competent
                                            transfer agent with respect to the Placement Agent Securities for a period of three (3) years
                                            after the Closing Date for so long as the Company has securities registered under the Exchange
                                            Act. In addition, from the date hereof until ninety (90) days after the Closing Date, subject
                                            to certain exceptions provided for in the Purchase Agreement, neither the Company nor any
                                            Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed
                                            issuance of any shares of Common Stock or Common Stock Equivalents, except that such restriction
                                            shall not apply with respect to an Exempt Issuance. From the date hereof until one hundred
                                            and eighty (180) days following the Closing Date, the Company shall be prohibited from effecting
                                            or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries
                                            of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving
                                            a Variable Rate Transaction, except that such restriction shall not apply with respect to
                                            an Exempt Issuance, and further provided that the issuance of shares of Common Stock in an
                                            &ldquo;at-the-market&rdquo; offering shall not be deemed a Variable Rate Transaction after
                                            thirty (30) days after the Closing Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            of the Placement Agent</U>. The Placement Agent represents and warrants that it (i)&nbsp;is
                                            a member in good standing of FINRA, (ii)&nbsp;is registered as a broker/dealer under the
                                            Exchange Act and the securities laws of each state in which an offer or sale of Placement
                                            Securities is made (unless exempt from the respective state&rsquo;s broker-dealer registration
                                            requirements), (iii)&nbsp;is licensed as a broker/dealer under the laws of the United States
                                            of America, applicable to the offers and sales of the Placement Agent Securities by the Placement
                                            Agent, (iv)&nbsp;is and will be a corporate body validly existing under the laws of its place
                                            of incorporation, and (v)&nbsp;has full power and authority to enter into and perform its
                                            obligations under this Agreement. The Placement Agent will immediately notify the Company
                                            in writing of any change in its status with respect to subsections (i) through (v) above.
                                            The Placement Agent covenants that it will use its reasonable best efforts to conduct the
                                            Placement hereunder in compliance with the provisions of this Agreement and the requirements
                                            of applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            consideration of the services to be provided for hereunder, the Company shall pay to the
                                            Placement Agent and/or its respective designees a cash fee of 7.00% of the aggregate gross
                                            proceeds raised from the sale of the Placement Agent Securities (the &ldquo;<B>Cash Fee</B>&rdquo;).
                                            The Cash Fee shall be paid on the Closing Date. The Company shall not be required to pay
                                            the Placement Agent any fees or expenses except for the Cash Fee and the reimbursement of
                                            (i) accountable legal fees and other reasonable and documented out-of-pocket expenses incurred
                                            by the Placement Agent in connection with the transaction in the amount of up to $70,000
                                            and (ii) non-accountable expenses equal to $20,000. As additional compensation for services
                                            rendered, on the Closing Date, the Company shall issue to the Placement Agent or its designees
                                            such number of common stock purchase warrants to purchase shares of Common Stock equal to
                                            5.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants sold in the
                                            Offering (the &ldquo;<B>Placement Agent Warrants</B>&rdquo;). The PA Warrants shall have
                                            the same terms as the Common Warrants sold to the investors in the Offering except that the
                                            exercise price shall be 110% of the per Share price of the Common Stock sold to the investors
                                            in the Offering, shall be exercisable six months from the issue date and shall provide for
                                            a cashless exercise provision which will be available regardless of the existence of a registration
                                            statement and customary anti-dilution provisions (for stock dividends and splits and recapitalizations).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Placement Agent reserves the right to reduce any item of compensation or adjust the terms
                                            thereof as specified herein in the event that a determination shall be made by FINRA to the
                                            effect that the Placement Agent&rsquo;s aggregate compensation is in excess of FINRA Rules
                                            or that the terms thereof require adjustment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company agrees to pay all costs, fees and expenses incurred by the Company in connection
                                            with the performance of its obligations hereunder and in connection with the transactions
                                            contemplated hereby, including, without limitation: (i) all expenses incident to the issuance,
                                            delivery and qualification of the Placement Agent Securities; (ii) all fees and expenses
                                            of the registrar and transfer agent of the Securities; (iii) all necessary issue, transfer
                                            and other stamp taxes in connection with the issuance and sale of the Placement Agent Securities;
                                            (iv) all fees and expenses of the Company&rsquo;s counsel, independent public or registered
                                            public accountants and other advisors; (v) all filing fees, reasonable attorneys&rsquo; fees
                                            and expenses incurred by the Company in connection with qualifying or registering (or obtaining
                                            exemptions from the qualification or registration of) all or any part of the Placement Agent
                                            Securities for offer and sale under the state securities or blue sky laws or the securities
                                            laws of any other country; and (vi) the fees and expenses associated with including the Placement
                                            Agent Securities on the Trading Market.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            the extent permitted by law, with respect to the Placement Agent Securities, the Company
                                            will indemnify the Placement Agent and its affiliates, directors, officers, employees, members
                                            and controlling persons (within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
                                            of the Exchange Act) against all losses, claims, damages, expenses and liabilities, as the
                                            same are incurred (including the reasonable fees and expenses of counsel), relating to or
                                            arising out of its activities hereunder or pursuant to this Agreement, except to the extent
                                            that any losses, claims, damages, expenses or liabilities (or actions in respect thereof)
                                            are found in a final judgment (not subject to appeal) by a court of law to have resulted
                                            primarily and directly from the Placement Agent&rsquo;s fraud, willful misconduct or gross
                                            negligence in performing the services described herein or violation of law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promptly
                                            after receipt by the Placement Agent of notice of any claim or the commencement of any action
                                            or proceeding with respect to which the Placement Agent is entitled to indemnity hereunder,
                                            the Placement Agent will notify the Company in writing of such claim or of the commencement
                                            of such action or proceeding, but failure to so notify the Company shall not relieve the
                                            Company from any obligation it may have hereunder, except and only to the extent such failure
                                            results in the forfeiture by the Company of substantial rights and defenses or materially
                                            adversely impacts the Company. If the Company so elects or is requested by the Placement
                                            Agent, the Company will assume the defense of such action or proceeding and will employ counsel
                                            reasonably satisfactory to the Placement Agent and will pay the reasonable actual and documented
                                            fees and expenses of such counsel. Notwithstanding the preceding sentence, the Placement
                                            Agent will be entitled to employ counsel separate from counsel for the Company and from any
                                            other party in such action if counsel for the Placement Agent reasonably determines that
                                            it would be inappropriate under the applicable rules of professional responsibility for the
                                            same counsel to represent both the Company and the Placement Agent. In such event, the reasonable
                                            fees and disbursements of no more than one (1) such separate counsel will be paid by the
                                            Company, in addition to fees of local counsel. The Company will have the right to settle,
                                            compromise, or consent to the entry of judgment in any pending or threatened the claim, action
                                            or proceeding provided that the Company will not settle any such claim, action or proceeding
                                            without the prior written consent of the Placement Agent, which will not be unreasonably
                                            withheld, conditioned, or delayed, unless such settlement includes an unconditional release
                                            of the Placement Agent and each other indemnitee named in such proceeding from all liabilities
                                            arising out of the action for such claim, action or proceeding. The Company shall not be
                                            liable for any settlement of any action effected without its written consent, which will
                                            not be unreasonably withheld, conditioned or delayed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company agrees to notify the Placement Agent promptly of the assertion against it or any
                                            other person of any claim or the commencement of any action or proceeding relating to a transaction
                                            contemplated by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            for any reason the foregoing indemnity is unavailable to the Placement Agent or insufficient
                                            to hold the Placement Agent harmless, then the Company shall contribute to the amount paid
                                            or payable by the Placement Agent as a result of such losses, claims, damages or liabilities
                                            in such proportion as is appropriate to reflect not only the relative benefits received by
                                            the Company on the one hand and the Placement Agent on the other, but also the relative fault
                                            of the Company on the one hand and the Placement Agent on the other that resulted in such
                                            losses, claims, damages or liabilities, as well as any relevant equitable considerations.
                                            The amounts paid or payable by a party in respect of losses, claims, damages and liabilities
                                            referred to above shall be deemed to include any legal or other fees and expenses incurred
                                            in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions
                                            hereof, the Placement Agent&rsquo;s share of the liability hereunder shall not be in excess
                                            of the amount of fees actually received by the Placement Agent under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            indemnification provisions shall remain in full force and effect whether or not the transaction
                                            contemplated by this Agreement is completed and shall survive the termination of this Agreement,
                                            and shall be in addition to any liability that the Company might otherwise have to any indemnified
                                            party under this Agreement or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Engagement
                                            Term</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Placement Agent&rsquo;s engagement hereunder will commence on the date hereof and continue
                                            through the Closing Date or, if earlier, April 17, 2026. The date of termination of this
                                            Agreement is referred to herein as the &ldquo;<B>Termination Date</B>.&rdquo; In the event,
                                            however, in the course of the Placement Agent&rsquo;s performance of due diligence it deems
                                            it necessary to terminate the engagement, the Placement Agent may do so prior to the Termination
                                            Date. The Company may elect to terminate the engagement hereunder for any reason prior to
                                            the Termination Date but will remain responsible for fees and expenses pursuant to Section&nbsp;3
                                            hereof and fees and expenses with respect to the Placement Agent Securities, if sold in the
                                            Placement. Notwithstanding anything to the contrary contained herein, the provisions concerning
                                            the Company&rsquo;s obligation to pay any fees or expenses actually earned pursuant to Section
                                            3 hereof and the provisions concerning confidentiality, indemnification, contribution and
                                            governing law contained herein will survive any expiration or termination of this Agreement.
                                            If this Agreement is terminated prior to the completion of the Placement, the Company shall
                                            reimburse expenses incurred by the Placement Agent as set forth herein but in no event greater
                                            than the amounts set forth herein, on or before the Termination Date. The Placement Agent
                                            agrees not to use any confidential information concerning the Company provided to the Placement
                                            Agent by the Company for any purposes other than those contemplated under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Placement
                                            Agent Information</U>. The Company agrees that any information or advice rendered by the
                                            Placement Agent in connection with this engagement is for the confidential use of the Company
                                            only in its evaluation of the Placement and, except as otherwise required by law, the Company
                                            will not disclose or otherwise refer to the advice or information in any manner without the
                                            Placement Agent&rsquo;s prior written consent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Fiduciary Relationship</U>. This Agreement does not create, and shall not be construed as
                                            creating rights enforceable by any person or entity not a party hereto, except those entitled
                                            hereto by virtue of the indemnification provisions hereof. The Company acknowledges and agrees
                                            that the Placement Agent is not and shall not be construed as a fiduciary of the Company
                                            and shall have no duties or liabilities to the equity holders or the creditors of the Company
                                            or any other person by virtue of this Agreement or the retention of the Placement Agent hereunder,
                                            all of which are hereby expressly waived.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing</U>.
                                            The obligations of the Placement Agent, and the closing of the sale of the Placement Agent
                                            Securities hereunder are subject to the accuracy, when made and on the Closing Date, of the
                                            representations and warranties on the part of the Company contained herein and in the Purchase
                                            Agreement, to the performance by the Company of its obligations hereunder and in the Purchase
                                            Agreement, and to each of the following additional terms and conditions, except as otherwise
                                            disclosed to and acknowledged and waived by the Placement Agent:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            corporate proceedings and other legal matters incident to the authorization, form, execution,
                                            delivery and validity of each of this Agreement, the Placement Agent Securities, and all
                                            other legal matters relating to this Agreement and the transactions contemplated hereby with
                                            respect to the Placement Agent Securities shall be reasonably satisfactory in all material
                                            respects to the Placement Agent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Placement Agent shall have received from outside counsel to the Company such counsel&rsquo;s
                                            written opinion with respect to the Placement Agent Securities, addressed to the Placement
                                            Agent and dated as of the Closing Date, in form and substance reasonably satisfactory to
                                            the Placement Agent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Placement Agent shall have received customary certificates of the Company&rsquo;s executive
                                            officers, as to the accuracy of the representations and warranties contained in the Purchase
                                            Agreement, and a certificate of the Company&rsquo;s secretary certifying that each of the
                                            Company&rsquo;s charter documents are true and complete, have not been modified and are in
                                            full force and effect; (ii) that the resolutions of the Company&rsquo;s Board of Directors
                                            relating to the Placement are in full force and effect and have not been modified; and (iii)
                                            as to the incumbency of the officers of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Common Stock shall be registered under the Exchange Act in accordance with the terms of the
                                            Purchase Agreement and, as of the Closing Date, the Company shall apply for the Shares and
                                            the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the Common
                                            Warrants to be listed and admitted and authorized for trading on the NYSE American or other
                                            applicable U.S. national exchange and satisfactory evidence of such application shall have
                                            been provided to the Placement Agent. The Company shall have taken no action designed to,
                                            or likely to have the effect of terminating the registration of the Common Stock under the
                                            Exchange Act or delisting or suspending from trading the Common Stock from the NYSE American
                                            or other applicable U.S. national exchange, nor has the Company received any information
                                            suggesting that the Commission or the NYSE American or other U.S. applicable national exchange
                                            is contemplating terminating such registration or listing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
                                            action shall have been taken and no statute, rule, regulation or order shall have been enacted,
                                            adopted or issued by any governmental agency or body which would, as of the Closing Date,
                                            prevent the issuance or sale of the Placement Agent Securities or materially and adversely
                                            affect the business or operations of the Company; and no injunction, restraining order or
                                            order of any other nature by any federal or state court of competent jurisdiction shall have
                                            been issued as of the Closing Date which would prevent the issuance or sale of the Placement
                                            Agent Securities or materially and adversely affect the business or operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company shall have entered into a Purchase Agreement with the Purchasers of the Placement
                                            Agent Securities and such agreement shall be in full force and effect and shall contain representations,
                                            warranties and covenants of the Company as agreed upon between the Company and the Purchasers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 47.5pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA
                                            shall have raised no objection to the fairness and reasonableness of the terms and arrangements
                                            of this Agreement. In addition, the Company shall, if requested by the Placement Agent, make
                                            or authorize Placement Agent&rsquo;s counsel to make on the Company&rsquo;s behalf, any necessary
                                            filing with the FINRA Corporate Financing Department with respect to the Placement and pay
                                            all filing fees required in connection therewith.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the conditions specified in this Section 8 shall not have been fulfilled when and as required by this Agreement, all obligations
of the Placement Agent hereunder may be cancelled by the Placement Agent at, or at any time prior to, the Closing Date. Notice of such
cancellation shall be given to the Company in writing or orally. Any such oral notice shall be confirmed promptly thereafter in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
                                            Law</U>. This Agreement will be governed by, and construed in accordance with, the laws of
                                            the State of New York applicable to agreements made and to be performed entirely in such
                                            State, without regard to its conflict of laws principles. This Agreement may not be assigned
                                            by either party without the prior written consent of the other party. This Agreement shall
                                            be binding upon and inure to the benefit of the parties hereto, and their respective successors
                                            and permitted assigns. Any right to trial by jury with respect to any dispute arising under
                                            this Agreement or any transaction or conduct in connection herewith is waived. Any dispute
                                            arising under this Agreement may be brought into the courts of the State of New York or into
                                            the Federal Court located in New York, New York and, by execution and delivery of this Agreement,
                                            the Company hereby accepts for itself and in respect of its property, generally and unconditionally,
                                            the jurisdiction of aforesaid courts. Each party hereto hereby irrevocably waives personal
                                            service of process and consents to process being served in any such suit, action or proceeding
                                            by delivering a copy thereof via overnight delivery (with evidence of delivery) to such party
                                            at the address in effect for notices to it under this Agreement and agrees that such service
                                            shall constitute good and sufficient service of process and notice thereof. Nothing contained
                                            herein shall be deemed to limit in any way any right to serve process in any manner permitted
                                            by law. If either party shall commence an action or proceeding to enforce any provisions
                                            of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
                                            by the other party for its attorney&rsquo;s fees and other costs and expenses incurred with
                                            the investigation, preparation and prosecution of such action or proceeding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire
                                            Agreement/Miscellaneous</U>. This Agreement embodies the entire agreement and understanding
                                            between the parties hereto, and supersedes all prior agreements and understandings, relating
                                            to the subject matter hereof. If any provision of this Agreement is determined to be invalid
                                            or unenforceable in any respect, such determination will not affect such provision in any
                                            other respect or any other provision of this Agreement, which will remain in full force and
                                            effect. This Agreement may not be amended or otherwise modified or waived except by an instrument
                                            in writing signed by both the Placement Agent and the Company. The representations, warranties,
                                            agreements and covenants contained herein shall survive the Closing Dates of the Placement
                                            and delivery of the Placement Agent Securities. This Agreement may be executed in two or
                                            more counterparts, all of which when taken together shall be considered one and the same
                                            agreement and shall become effective when counterparts have been signed by each party and
                                            delivered to the other party, it being understood that both parties need not sign the same
                                            counterpart. In the event that any signature is delivered by facsimile transmission or a
                                            .pdf format file, such signature shall create a valid and binding obligation of the party
                                            executing (or on whose behalf such signature is executed) with the same force and effect
                                            as if such facsimile or .pdf signature page were an original thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
                                            Any and all notices or other communications or deliveries required or permitted to be provided
                                            hereunder shall be in writing and shall be deemed given and effective on the earliest of
                                            (a) the date of transmission, if such notice or communication is sent to the email address
                                            specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time)
                                            on a business day, (b) the next business day after the date of transmission, if such notice
                                            or communication is sent to the email address on the signature pages attached hereto on a
                                            day that is not a business day or later than 6:30 p.m. (New York City time) on any business
                                            day, (c) the third business day following the date of mailing, if sent by U.S. internationally
                                            recognized air courier service, or (d) upon actual receipt by the party to whom such notice
                                            is required to be given. The address for such notices and communications shall be as set
                                            forth on the signature pages hereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Press
                                            Announcements</U>. The Company agrees that the Placement Agent shall, on and after the Closing
                                            Date, have the right to reference the Placement and the Placement Agent&rsquo;s role in connection
                                            therewith in the Placement Agent&rsquo;s marketing materials and on its website and to place
                                            advertisements in financial and other newspapers and journals, in each case at its own expense
                                            and in compliance with all applicable securities laws and applicable confidentiality provisions.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>The
remainder of this page has been intentionally left blank.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
confirm that the foregoing correctly sets forth our agreement by signing and returning to the Placement Agent the enclosed copy of this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Ceros
    Financial Services, inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Mark Goldwasser</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    Goldwasser</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
                                            for notice:</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1445
    Research Boulevard<BR>
    Rockville, Maryland 20850<BR>
    Attn: Mark Goldwasser<BR>
    Email: goldie@cerosfs.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and agreed to as of<BR>
the date first written above:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="text-transform: uppercase"><B>OS
                                            Therapies Incorporated</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Paul A. Romness, MPH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    A. Romness, MPH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
for notice</U>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OS
Therapies Incorporated<BR>
Attn: Paul A. Romness, MPH, President and Chief Executive Officer<BR>
115 Pullman Crossing Road, Suite #103<BR>
Grasonville, Maryland 21638</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
par@ostherapies.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page to Placement Agency Agreement.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ea028448801ex4-1.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRE-FUNDED</B>&nbsp;<B>COMMON STOCK PURCHASE
WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>OS Therapies
Incorporated</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 50%; font-size: 10pt"><B>Warrant Shares: __________</B></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><B>Issue Date: __________, 2026</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.9in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, __________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from <FONT STYLE="text-transform: uppercase"><B>OS Therapies Incorporated,</B></FONT>
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to <B>__________ </B>shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated March 31, 2026, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify"><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in
whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the
Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto as
<U>Exhibit A</U> (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii)&nbsp;the number
of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the
Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares
available hereunder and this Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company
for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify"><U>Exercise Price</U>. The aggregate exercise price of this Warrant, except for a nominal exercise price
of $0.001 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date and, consequently, no additional consideration
(other than the nominal exercise price of $0.001 per Warrant Share) shall be required to be paid by the Holder to any Person to effect
any exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such pre-paid aggregate
exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under
this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify"><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement
registering, or the prospectus contained therein is not available for the issuance or resale of the Warrant Shares to or by the Holder,
then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the
Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt">(A)</TD>
    <TD STYLE="width: 0.15in; text-align: justify; font-size: 10pt">=</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">(B)</TD>
    <TD STYLE="text-align: justify; width: 0.15in">=</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">the Exercise Price of this Warrant, as adjusted hereunder;
and</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">(X)</TD>
    <TD STYLE="vertical-align: top; text-align: justify"> =</TD>
    <TD STYLE="vertical-align: top; text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&ldquo;<U>Bid Price</U>&rdquo; means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">&ldquo;<U>VWAP</U>&rdquo; means, for
any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on
a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">If Warrant Shares are issued in such
a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares
shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to
this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;), provided that the
aggregate Exercise Price is received by the Company on the Warrant Share Delivery Date (other than in connection with a cashless exercise).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.
Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:00 a.m. (New York City time) on the
Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to
deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise
Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than
in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including reasonable and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at
the option of the Holder, either reinstate the portion of this Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of this Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round down to the lesser whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that
after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the
foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall
include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being
made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e),
beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.
To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have
no liability for exercise of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than in connection
with information provided in connection with clause (C) below). In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the
case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written request of a Holder, the Company shall within one (1)
Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares
of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99/9.99]% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this
Warrant. The Holder, upon written notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this
Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder
and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section&nbsp;2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify"><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays
a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the
Company upon exercise of this Warrant), (ii)&nbsp;subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)&nbsp;issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify"><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section&nbsp;3(a) above,
if at any time while this Warrant is outstanding, the Company grants, issues or sells any Common Stock Equivalents or rights to purchase
stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase
Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in
such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify"><U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly
or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)
the Company or any Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon
any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable
upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and
the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally
with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall
assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the
avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the
Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction
occurs prior to the Initial Exercise Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest
1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">f)</TD><TD STYLE="text-align: justify"><U>Notice to Holder</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: 48.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-indent: 0.5in; text-align: justify">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify"><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify"><U>New Warrants</U>. Subject to compliance with applicable securities laws, this Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying
the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new
Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued
on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as
to the number of Warrant Shares issuable pursuant thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify"><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the
Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company
may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify"><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the
Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company
be required to net cash settle an exercise of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">b)</TD><TD STYLE="text-align: justify"><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate
relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which,
in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">c)</TD><TD STYLE="text-align: justify"><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or
the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be
exercised on the next succeeding Trading Day.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Authorized Shares</U>. The Company covenants that, during the period this Warrant is outstanding,
                                                             it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the
                                                             Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this
                                                             Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon
                                                             the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to
                                                             assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any
                                                             requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
                                                             may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights
                                                             represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully
                                                             paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than
                                                             taxes in respect of any transfer occurring contemporaneously with such issue).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not
increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: justify">Before taking any action, which would
result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall
obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies
having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation
of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without
regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors,
officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting
in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any
claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is
an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of
this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">f)</TD><TD STYLE="text-align: justify"><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this
Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and
federal securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">g)</TD><TD STYLE="text-align: justify"><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder
on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies, notwithstanding
the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other provision of this Warrant,
if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited
to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">h)</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holder
hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a
nationally recognized overnight courier service, addressed to the Company, at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland
21638, Attention: Chief Financial Officer, email address: cfo@ostherapies.com, or such other email address or address as the Company may
specify for such purposes by notice to the Holder. Any and all notices or other communications or deliveries to be provided by the Company
hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication
or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the
next Trading Day after the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth
in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading
Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the
party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Company or any Subsidiaries, the Company shall promptly file such notice with the Commission pursuant
to a Current Report on Form 8-K.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">i)</TD><TD STYLE="text-align: justify"><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder
to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise
to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is
asserted by the Company or by creditors of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">j)</TD><TD STYLE="text-align: justify"><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including
recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages
would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">k)</TD><TD STYLE="text-align: justify"><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and
obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and
the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time
to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">l)</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written
consent of the Company, on the one hand, and the Holder, on the other hand.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">m)</TD><TD STYLE="text-align: justify"><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner
as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable
law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.15in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">n)</TD><TD STYLE="text-align: justify"><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this Warrant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>OS Therapies Incorporated</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%"> Paul A. Romness, MPH</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: </TD>
    <TD>President and Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 5.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: 0pt"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TO: <FONT STYLE="text-transform: uppercase"><B>OS
Therapies Incorporated</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby
elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the
form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 81pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.2in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.2in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.2in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.35in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.2in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: __________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9.45pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9.45pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9.45pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9.45pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; text-align: justify">Name:</TD>
    <TD STYLE="width: 33%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address: </TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ea028448801ex4-2.htm
<DESCRIPTION>FORM OF COMMON WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>OS Therapies
Incorporated</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Warrant Shares: _______</TD>
  <TD STYLE="text-align: right; width: 50%">Issue Date: _______,
20__ (the &ldquo;<U>Issue Date</U>&rdquo;)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE
WARRANT (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Issue Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on _______, 20__<SUP>1</SUP>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from <FONT STYLE="text-transform: uppercase"><B>OS
Therapies Incorporated</B>,</FONT> a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______&nbsp;shares (as subject to
adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Insert the date that is the five (5) year anniversary of
the Issue Date, provided that, if such date is not a Trading Day, insert the immediately following Trading Day.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of March 31, 2026, among the Company and the purchasers listed
on the signature pages thereto, as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, NY 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i)&nbsp;one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.40, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at
the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or
(z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the
date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof
after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"> i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;), provided that the aggregate Exercise Price is received by the Company on the Warrant Share Delivery Date (other than in connection with a cashless exercise). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:00 a.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including reasonable and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at
the option of the Holder, either reinstate the portion of this Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of this Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round down to the lesser whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercise of this Warrant
that are not in compliance with the Beneficial Ownership Limitation (other than in connection with information provided in connection
with clause (C) below). In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon written notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) Reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant is outstanding,
the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro
rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be
entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the
voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common equity
of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and
approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver
to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity
(or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard
to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the
exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant
to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise
price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation
of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity
or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the
Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other
Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had
been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section
3(e) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or
(ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. Subject to compliance with applicable securities laws, this Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which
new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer
which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for
the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall
be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares
issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638, Attention: Chief Financial Officer, email address:
cfo@ostherapies.com, or such other email address or address as the Company may specify for such purposes by notice to the Holder. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such
Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective
on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth
in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such
notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or
later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S.
nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.
To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any
Subsidiaries, the Company shall promptly file such notice with the Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>OS Therapies Incorporated</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">OS Therapies Incorporated</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">Name:</TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><U> </U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><U> </U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Phone Number:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email Address:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature:_______________________________<U> </U></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address:________________________________<U> </U></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>5
<FILENAME>ea028448801ex4-3.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OS
Therapies Incorporated</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    Shares: _______</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: _______, 20__</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: _______, 20__</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after _______, 20__<SUP>1</SUP> (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior
to 5:00 p.m. (New York City time) on _______, 20__<SUP>2</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from <FONT STYLE="text-transform: uppercase"><B>OS Therapies Incorporated</B>,</FONT> a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______&nbsp;shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1.</U> <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insert
the date that is the six (6) month anniversary of the Issue Date, provided that, if such date is not a Trading Day, insert the immediately
following Trading Day.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insert
the date that is the five (5) year anniversary of the Issue Date, provided that, if such date is not a Trading Day, insert the immediately
following Trading Day.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchase
Agreement</U>&rdquo; means the Securities Purchase Agreement, dated as of March 31, 2026, among the Company and the purchasers listed
on the signature pages thereto, as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent Agreement</U>&rdquo; means the Placement Agent Agreement, dated as of March 31, 2026, between the Placement Agent and the Company,
as amended, modified or supplemented from time to time in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette Place,
Woodmere, NY 11598 and an email address of info@vstocktransfer.com, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Placement Agent Common Stock Purchase Warrants issued by the Company pursuant to the Placement Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2.</U>&nbsp; <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i)&nbsp;one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as
defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price
for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States
bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and this Warrant has been exercised
in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the
date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a
portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall
maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection
to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this
Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant
Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated
on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.54, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance or resale of the Warrant Shares to or by the Holder, then this Warrant may also be exercised,
in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number
of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 99pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT>
                            =</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common
Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT>
                            =</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT>
                            =</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section&nbsp;2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;), provided that the aggregate Exercise Price is received by the Company on the Warrant Share Delivery Date (other than in connection with a cashless exercise). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP>rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 9:00 a.m. (New York City time) on the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by
its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including reasonable and customary brokerage commissions, if any) for the shares of Common Stock
so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver
to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation
was executed, and (B) at the option of the Holder, either reinstate the portion of this Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted
exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A)
of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written
notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in
equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure
to timely deliver shares of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round down to the lesser whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercise of this Warrant
that are not in compliance with the Beneficial Ownership Limitation (other than in connection with information provided in connection
with clause (C) below). In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written request of a Holder, the Company shall within one (1) Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was
reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance
of any Warrants, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. The Holder, upon written notice to the Company, may increase or decrease the
Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the
Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3.</U>&nbsp; <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) Reserved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant is outstanding,
the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or
more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power of the common
equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the
Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to
the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the
exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and
the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally
with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall
assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect
as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the
avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the
Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction
occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4 .</U>&nbsp;<U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
Pursuant to FINRA Rule 5110(g), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result
in the effective economic disposition of this Warrant or any Warrant Shares issued upon exercise of this Warrant by any person for a
period of 180 days immediately following the date of commencement of sales of the offering pursuant to which this Warrant is being issued,
except (i) to Ceros Financial Services, Inc. or a placement agent or a selected dealer participating in the offering pursuant to which
this Warrant is being issued or (2) as provided for in FINRA Rule 5110(g)(2). Subject to the foregoing restriction, this Warrant and
all rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or
its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees,
as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a
new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned
this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance
herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. Subject to compliance with applicable securities laws, this Warrant may be divided or combined with other Warrants upon
presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in
which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any
transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange
for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall
be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares
issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5.</U>&nbsp; <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock
a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holder hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed
to the Company, at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638, Attention: Chief Financial Officer, email address:
cfo@ostherapies.com, or such other email address or address as the Company may specify for such purposes by notice to the Holder. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall promptly file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OS
    Therapies Incorporated</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">OS
                                                                                                                                                                                           Therapies Incorporated</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
lawful money of the United States; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase
shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">Name:</TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 49%; text-align: justify"><U> </U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><U> </U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Phone Number:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Email Address:</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature:_______________________________<U> </U></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address:________________________________<U> </U></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>6
<FILENAME>ea028448801ex5-1.htm
<DESCRIPTION>OPINION OF OLSHAN FROME WOLOSKY LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028448801_ex5-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">April 2, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OS Therapies Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">115 Pullman Crossing Road, Suite 103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grasonville, Maryland 21638</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are acting as legal counsel
to OS Therapies Incorporated, a Delaware corporation (the &ldquo;Company&rdquo;), in connection with the offer and sale by the Company
of (i) 2,505,073 shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;),
(ii) pre-funded warrants to purchase up to 1,250,893 shares of Common Stock (the &ldquo;Pre-Funded Warrants&rdquo;), (iii) warrants to
purchase up to 3,755,966 shares of Common Stock (the &ldquo;Common Warrants&rdquo;), (iv) warrants to purchase up to 187,798 shares of
Common Stock (the &ldquo;Placement Agent Warrants&rdquo;) and (v) up to 5,194,657 shares of Common Stock issuable upon exercise of the
Pre-Funded Warrants, Common Warrants and Placement Agent Warrants (the &ldquo;Warrant Shares&rdquo; and, collectively with the Shares,
Pre-Funded Warrants, Common Warrants and Placement Agent Warrants, the &ldquo;Securities&rdquo;), pursuant to the Company&rsquo;s Registration
Statement on Form S-3 (Registration No. 333-289443) (the &ldquo;Registration Statement&rdquo;), filed by the Company with the Securities
and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities Act of 1933, as amended (the &ldquo;Act&rdquo;), on August
8, 2025 and declared effective by the Commission on August 12, 2025, including the base prospectus, dated August 25, 2025, constituting
a part of the Registration Statement, filed by the Company with the Commission pursuant to Rule 424(b)(3) under the Act on August 25,
2025 (the &ldquo;Base Prospectus&rdquo;), as supplemented by the prospectus supplement, dated March 31, 2026, filed by the Company with
the Commission pursuant to Rule 424(b)(5) under the Act on April 2, 2026 (such prospectus supplement, together with the Base Prospectus,
the &ldquo;Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with this opinion
letter, we have examined (a) the Registration Statement, (b) the Prospectus, (c) the Pre-Funded Warrants, (d) the Common Warrants, (e)
the Placement Agent Warrants, (f) the Third Amended and Restated Certificate of Incorporation of the Company, as amended to date, (g)
the Amended and Restated Bylaws of the Company, as amended to date, and (h) certain resolutions of the Board of Directors of the Company
relating to the issuance, sale and registration of the Securities. In addition, we have examined and relied upon such corporate records
of the Company, and have made such examination of law, as we have deemed necessary or appropriate for purposes of the opinions expressed
below. As to certain factual matters, unless otherwise indicated, we have relied, to the extent we have deemed proper, on certificates
of certain officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea028448801_ex5-1img2.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 2, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have assumed for purposes
of rendering the opinions set forth herein, without any verification by us, the genuineness of all signatures, the legal capacity of all
natural persons to execute and deliver documents, the authenticity and completeness of documents submitted to us as originals, the completeness
and conformity with authentic original documents of all documents submitted to us as copies, and that all documents, books and records
made available to us by the Company are accurate and complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon, subject to and
limited by the foregoing, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Shares have been duly authorized by the Company and, upon issuance, delivery and payment therefor
in the manner contemplated by the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The Pre-Funded Warrants, Common Warrants and the Placement Agent Warrants have been duly authorized by
the Company and, when executed and delivered by the Company in the manner contemplated by the Registration Statement and the Prospectus,
will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms,
except (i) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or
at law), (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws, (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefor may be brought and (iv) that we express no opinion as
to whether a state court outside of the State of New York or a federal court of the United States would give effect to the choice of New
York law provided for in the Pre-Funded Warrants, Common Warrants and Placement Agent Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The Warrant Shares have been duly authorized by the Company and, when issued, delivered and paid for upon
valid exercise in accordance with the terms of the Pre-Funded Warrants, Common Warrants or Placement Agent Warrants, as applicable, will
be validly issued, fully paid and nonassessable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are members of the Bar
of the State of New York. We do not express any opinion as to the effect of any laws other than the laws of the State of New York and
the General Corporation Law of the State of Delaware, and the federal laws of the United States of America, as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter speaks only at
and as of its date and is based solely on the facts and circumstances known to us at and as of such date. We assume no obligation to revise
or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in fact or law
that may hereafter occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 2, 2026</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Page 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby consent to the filing
of this opinion in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Act with the Commission
as an exhibit to the Current Report on Form 8-K to be filed by the Company in connection with the issuance and sale of the Securities
and to the use of our name in the Prospectus under the caption &ldquo;Legal Matters.&rdquo; In giving such consent, we do not hereby admit
that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>/s/ Olshan Frome Wolosky LLP</U></I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OLSHAN FROME WOLOSKY LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>7
<FILENAME>ea028448801ex10-1.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of March 31, 2026, between OS Therapies Incorporated,
a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo; and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to&#8239;an effective registration statement under the Securities
Act (as defined herein), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
1. DEFINITIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U>.
                                            In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement,
                                            the following terms have the meanings set forth in this Section&nbsp;1.1:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Laws</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(nn).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday, any date which is a federal legal holiday in the United States or other day
on which commercial banks in The City of New York are authorized or required by law or government action to remain closed; provided,
however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &ldquo;stay
at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any other similar orders or restrictions or the
closure of any physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems
(including for wire transfers) of commercial banks in The City of New York are generally are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii)&nbsp;the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2nd) Trading Day following the date hereof if this Agreement is signed on a day that is
not a Trading Day or after 4:00pm (New York City time) and before midnight (New York City time) on a Trading Day).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the Common Stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon exercise of the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section&nbsp;2.2(a) hereof,
which Common Warrants shall be immediately exercisable upon issuance and shall expire five (5) years from the date of issuance, in the
form of <U>Exhibit&nbsp;B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Company
Counsel</U>&rdquo; means Olshan Frome Wolosky LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Schedules</U>&rdquo; means the Disclosure Schedules of the Company delivered concurrently herewith, which such Disclosure Schedules shall
be deemed a part hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, options, restricted stock units, or other equity awards to employees,
consultants, contractors, advisors, officers or directors of the Company pursuant to any stock or option plan or incentive plan or employee
stock purchase plan duly adopted for such purpose, (b)&nbsp;securities (including options, rights or warrants) exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have
not been voluntarily amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price,
exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term
of such securities, (c)&nbsp;shares of Common Stock or securities exercisable or exchangeable for, or convertible into, shares of Common
Stock sold to employees, directors, consultants, or any of their affiliated entities in the ordinary course of business or pursuant to
agreements or in connection with commitments in place as of the date hereof, and (d)&nbsp;securities issued pursuant to acquisitions
or strategic transactions approved by a majority of the disinterested directors of the Company, provided in the case of each of clauses
(c) and (d) that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration
rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.11(a)
herein, and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset and shall provide to the Company additional benefits in addition to the
investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(nn).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section&nbsp;3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Governmental
Authority</U>&rdquo; means any court or arbitrator or governmental or regulatory authority or third party with jurisdiction over the
Company or any of its Subsidiaries or their respective assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(p).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(f)(ii).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>IT
Systems and Data</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(mm).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and executive
officers, in the form of <U>Exhibit A</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning ascribed to such term in Section&nbsp;3.1(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; equals $1.40, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Per
Pre-Funded Warrant Purchase Price</U>&rdquo; shall be the Per Share Purchase Price minus $0.001, subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions relating to the Common Stock that occur after
the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Placement
Agent</U>&rdquo; means Ceros Financial Services, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the warrants delivered to the Purchasers at Closing in accordance with Section 2.2(a) hereof,
which Pre-Funded Warrants shall be exercisable immediately upon issuance and shall expire when exercised in full, in the form of <U>Exhibit
C</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the base prospectus filed under the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that will be filed with
the Commission and delivered by the Company to each Purchaser at or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with the Commission on Form S-3 (File No. 333-289443), as amended, including
all information, documents and exhibits filed with or incorporated by reference into such registration statement, which registers the
sale of the Securities and includes any Rule&nbsp;462(b) Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule&nbsp;462(b)
Registration Statement</U>&rdquo; means any registration statement prepared by the Company registering additional Securities, which was
filed with the Commission on or prior to the date hereof and became automatically effective pursuant to Rule&nbsp;462(b) promulgated
by the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Reports</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(h).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities</U>&rdquo;
means the Shares, Pre-Funded Warrants, Pre-Funded Warrant Shares, Common Warrants and Common Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below such
Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States
dollars and in immediately available funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any significant subsidiary of the Company within the meaning of Rule 1-02(w) under Regulation S-X and shall, where applicable,
also include any direct or indirect significant subsidiary of the Company formed or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Common Warrants, the Lock-Up Agreements and all exhibits and
schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means the Pre-Funded Warrants and the Common Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrant
Shares</U>&rdquo; means the Pre-Funded Warrant Shares and the Common Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
2. PURCHASE AND SALE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing</U>.
                                            On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company
                                            agrees to sell, and the Purchasers, severally and not jointly, agree to purchase (i)&nbsp;the
                                            number of shares of Common Stock set forth under the heading &ldquo;Subscription Amount&rdquo;
                                            on the Purchaser&rsquo;s signature page hereto, at the Per Share Purchase Price and (ii)&nbsp;Common
                                            Warrants exercisable for shares of Common Stock as calculated pursuant to Section 2.2(a);
                                            <U>provided</U>, <U>however</U>, that, to the extent that a Purchaser determines, in its
                                            sole discretion, that such Purchaser (together with such Purchaser&rsquo;s Affiliates, and
                                            any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s
                                            Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, or as
                                            such Purchaser may otherwise choose, in lieu of purchasing shares of Common Stock, such Purchaser
                                            may elect to purchase Pre-Funded Warrants in such manner to result in the full Subscription
                                            Amount being paid by such Purchaser to the Company. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
                                            shall be 4.99% (or, at the election of the Purchaser, 9.99%) of the number of shares of Common
                                            Stock, in each case, immediately after giving effect to the issuance of the Securities on
                                            the Closing Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for
Delivery Versus Payment (&ldquo;<U>DVP</U>&rdquo;) settlement with the Company or its designees. The Company shall deliver to each Purchaser
its respective Shares and Pre-Funded Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver
the other items set forth in Section 2.2 at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2
and 2.3, the Closing shall occur remotely via the exchange of documents and signatures or such other location as the parties shall mutually
agree. Unless otherwise directed by the Placement Agent, settlement of the Shares shall occur via DVP (i.e., on the Closing Date, the
Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to
the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically
deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by
wire transfer to the Company). Notwithstanding anything herein to the contrary, if at any time on or after the time of execution of this
Agreement by the Company and an applicable Purchaser through, and including the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement
Period</U>&rdquo;), such Purchaser sells to any Person all, or any portion, of any Securities to be issued hereunder to such Purchaser
at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;), such Person shall, automatically hereunder (without any
additional required actions by such Purchaser or the Company), be deemed to be a Purchaser under this Agreement unconditionally bound
to purchase, and the Company shall be deemed unconditionally bound to sell, such Pre-Settlement Shares to such Person at the Closing;
provided that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s receipt
of the Subscription Amount for such Pre-Settlement Shares hereunder; and provided, further, that the Company hereby acknowledges and
agrees that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not such Purchaser will
elect to sell any Pre-Settlement Shares during the Pre-Settlement Period. The decision to sell any shares of Common Stock by such Purchaser
shall solely be made at the time such Purchaser elects to effect any such sale, if any. Notwithstanding the foregoing, with respect to
any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered on or prior to 9:00 a.m. (New York City time) on the Closing
Date, which may be delivered at any time after the time of execution of this Agreement, the Company agrees to deliver the Pre-Funded
Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Closing Date and the Closing Date shall be the Warrant
Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes hereunder. Notwithstanding anything to the contrary herein and
a Purchaser&rsquo;s Subscription Amount set forth on the signature pages attached hereto, the number of Shares purchased by a Purchaser
(and its Affiliates) hereunder shall not, when aggregated with all other shares of Common Stock owned by such Purchaser (and its Affiliates)
at such time, result in such Purchaser beneficially owning (as determined in accordance with Section 13(d) of the Exchange Act) in excess
of 9.99% of the then issued and outstanding Common Stock outstanding at the Closing (the &ldquo;<U>Beneficial Ownership Maximum</U>&rdquo;),
and such Purchaser&rsquo;s Subscription Amount, to the extent it would otherwise exceed the Beneficial Ownership Maximum immediately
prior to the Closing, shall be conditioned upon the issuance of Shares at the Closing to the other Purchasers signatory hereto. To the
extent that a Purchaser&rsquo;s beneficial ownership of the Shares would otherwise be deemed to exceed the Beneficial Ownership Maximum,
such Purchaser&rsquo;s Subscription Amount shall automatically be reduced as necessary in order to comply with this paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Deliveries</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            or prior to the Closing Date, the Company shall deliver or cause to be delivered to each
                                            Purchaser the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            Agreement duly executed by the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
                                            opinion of Company Counsel, in a form reasonably acceptable to the Placement Agent and Purchasers;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
                                            to deliver, on an expedited basis, in book entry form (unless otherwise requested by the
                                            Purchasers) a number of Shares equal to such Purchaser&rsquo;s Subscription Amount divided
                                            by the Per Share Purchase Price, registered in the name of such Purchaser;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief Executive
                                            Officer or Chief Financial Officer;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities
                                            Act);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            Officer&rsquo;s Certificate, in form and substance reasonably satisfactory to the Placement
                                            Agent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Secretary&rsquo;s Certificate, in form and substance reasonably satisfactory to the Placement
                                            Agent;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
                                            each Purchaser of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered
                                            in the name of such Purchaser to purchase up to a number of shares of Common Stock equal
                                            to the portion of such Purchaser&rsquo;s Subscription Amount applicable to the Pre-Funded
                                            Warrants divided by the sum of the Per Pre-Funded Warrant Purchase Price, subject to adjustment
                                            therein;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Lock-Up Agreements; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            Common Warrant registered in the name of each Purchaser to purchase up to a number of shares
                                            of Common Stock equal to 100% of the Purchaser&rsquo;s Shares, with an exercise price equal
                                            to $1.40, subject to adjustment therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the
                                            Company the following:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">this
                                            Agreement duly executed by such Purchaser; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Closing
                                            Conditions</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            obligations of the Company hereunder in connection with the Closing are subject to the following
                                            conditions being met:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            accuracy in all material respects (or, to the extent representations or warranties are qualified
                                            by materiality or Material Adverse Effect, in all respects) on the Closing Date of the representations
                                            and warranties of the Purchasers contained herein (unless such representation or warranty
                                            is as of a specific date therein in which case they shall be accurate in all material respects
                                            (or, to the extent representations or warranties are qualified by materiality or Material
                                            Adverse Effect, in all respects) as of such date);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            obligations, covenants and agreements of each Purchaser required to be performed at or prior
                                            to the Closing Date shall have been performed; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            respective obligations of the Purchasers hereunder in connection with the Closing are subject
                                            to the following conditions being met:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            accuracy in all material respects (or, to the extent representations or warranties are qualified
                                            by materiality or Material Adverse Effect, in all respects) when made and on the Closing
                                            Date of the representations and warranties of the Company contained herein (unless such representation
                                            or warranty is as of a specific date therein in which case they shall be accurate in all
                                            material respects (or, to the extent representations or warranties are qualified by materiality
                                            or Material Adverse Effect, in all respects) as of such date);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            obligations, covenants and agreements of the Company required to be performed at or prior
                                            to the Closing Date shall have been performed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            shall have been no Material Adverse Effect with respect to the Company since the date hereof;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from
                                            the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended
                                            by the Commission or the Company&rsquo;s principal Trading Market, and, at any time prior
                                            to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
                                            not have been suspended or limited, or minimum prices shall not have been established on
                                            securities whose trades are reported by such service, or any Trading Market, nor shall a
                                            banking moratorium have been declared either by the United States or New York State authorities
                                            nor shall there have occurred any material outbreak or escalation of hostilities or other
                                            national or international calamity of such magnitude in its effect on, or any material adverse
                                            change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
                                            makes it impracticable or inadvisable to purchase the Securities at the Closing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
3. REPRESENTATIONS AND WARRANTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            and Warranties of the Company</U>. Except as set forth in the SEC Reports, which qualify
                                            these representations and warranties in their entirety, or in the Disclosure Schedules, which
                                            Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or
                                            otherwise made herein to the extent of the disclosure contained in the corresponding section
                                            of the Disclosure Schedules, the Company hereby makes the following representations and warranties
                                            to each Purchaser:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsidiaries</U>.
                                            All of the direct and indirect Subsidiaries of the Company are set forth in the SEC Reports.
                                            The Company owns, directly or indirectly, all of its capital stock or other equity interests
                                            of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
                                            of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
                                            and free of preemptive and similar rights to subscribe for or purchase securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organization
                                            and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated
                                            or otherwise organized, validly existing and in good standing under the laws of the jurisdiction
                                            of its incorporation or organization, with the requisite power and authority to own and use
                                            its properties and assets and to carry on its business as currently conducted. Neither the
                                            Company nor any Subsidiary is in violation nor default of any of the provisions of its respective
                                            certificate or articles of incorporation, bylaws or other organizational or charter documents.
                                            Each of the Company and the Subsidiaries is duly qualified to conduct business and is in
                                            good standing as a foreign corporation or other entity in each jurisdiction in which the
                                            nature of the business conducted or property owned by it makes such qualification necessary,
                                            except where the failure to be so qualified or in good standing, as the case may be, could
                                            not have or reasonably be expected to result in: (i) a material adverse effect on the legality,
                                            validity or enforceability of any Transaction Document, (ii) a material adverse effect on
                                            the results of operations, assets, business, prospects or condition (financial or otherwise)
                                            of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect
                                            on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations
                                            under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;)
                                            and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing
                                            or seeking to revoke, limit or curtail such power and authority or qualification.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization;
                                            Enforcement</U>. The Company has the requisite corporate power and authority to enter into
                                            and to consummate the transactions contemplated by this Agreement and each of the other Transaction
                                            Documents and otherwise to carry out its obligations hereunder and thereunder. The execution
                                            and delivery of this Agreement and each of the other Transaction Documents by the Company
                                            and the consummation by it of the transactions contemplated hereby and thereby have been
                                            duly authorized by all necessary action on the part of the Company and no further action
                                            is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in
                                            connection herewith or therewith other than in connection with the Required Approvals. This
                                            Agreement and each other Transaction Document to which it is a party has been (or upon delivery
                                            will have been) duly executed by the Company and, when delivered in accordance with the terms
                                            hereof and thereof, will constitute the valid and binding obligation of the Company enforceable
                                            against the Company in accordance with its terms, except (i) as limited by general equitable
                                            principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws
                                            of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as
                                            limited by general equitable principles and laws relating to the availability of specific
                                            performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
                                            and contribution provisions may be limited by applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and
                                            the other Transaction Documents to which it is a party, the issuance and sale of the Securities
                                            and the consummation by it of the transactions contemplated hereby and thereby do not and
                                            will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s
                                            certificate or articles of incorporation or bylaws or other organizational or charter documents,
                                            or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
                                            time or both would become a default) under, result in the creation of any Lien upon any of
                                            the properties or assets of the Company or any Subsidiary, or give to others any rights of
                                            termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
                                            (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
                                            or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding
                                            to which the Company or any Subsidiary is a party or by which any property or asset of the
                                            Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals,
                                            conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction,
                                            decree or other restriction of any court or governmental authority to which the Company or
                                            a Subsidiary is subject (including federal and state securities laws and regulations), or
                                            by which any property or asset of the Company or a Subsidiary is bound or affected; except
                                            in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected
                                            to result in a Material Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings,
                                            Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization
                                            or order of, give any notice to, or make any filing or registration with, any court or other
                                            federal, state (including state blue sky law), local or other governmental authority or other
                                            Person in connection with the execution, delivery and performance by the Company of the Transaction
                                            Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement,
                                            (ii) the filing with the Commission of the Prospectus Supplement, and (iii) notices and/or
                                            application(s) to and approvals by each applicable Trading Market for the listing of the
                                            Shares for trading thereon in the time and manner required thereby and (iv) filings required
                                            by the Financial Industry Regulatory Authority (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).
                                            All references in this Agreement to the Registration Statement, the Prospectus, the Prospectus
                                            Supplement or any Issuer Free Writing Prospectus, or any amendments or supplements to any
                                            of the foregoing, shall be deemed to include any copy thereof filed with the Commission on
                                            EDGAR.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Issuance
                                            of the Securities; Qualification; Registration; Securities Act Compliance and No Stop Orders</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Shares and Warrant Shares are duly authorized and, when issued and paid for in accordance
                                            with the applicable Transaction Documents, will be duly and validly issued, fully paid and
                                            non-assessable, free and clear of all Liens imposed by the Company, except for restrictions
                                            set forth in the Transaction Documents. The Warrants have been duly authorized by the Company
                                            and, when executed and delivered by the Company, will constitute valid and binding obligations
                                            of the Company, enforceable against the Company in accordance with their terms, subject to
                                            applicable bankruptcy, insolvency, reorganization, moratorium and similar laws affecting
                                            creditors&rsquo; rights generally and general principles of equity. The Securities are not
                                            and will not be subject to the preemptive rights of any holders of any security of the Company
                                            or similar contractual rights granted by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.6in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has prepared and filed the Registration Statement in conformity with the requirements
                                            of the Securities Act, which Registration Statement became effective on August 25, 2025,
                                            including the Prospectus, and such amendments and supplements thereto as may have been required
                                            to the date of this Agreement. The Registration Statement is effective under the Securities
                                            Act and, to the Company&rsquo;s knowledge, no stop order preventing or suspending the effectiveness
                                            of the Registration Statement or suspending or preventing the use of the Prospectus has been
                                            issued by the Commission and no proceedings for that purpose have been instituted or, to
                                            the knowledge of the Company, are threatened by the Commission. The Company, if required
                                            by the rules and regulations of the Commission, shall file the Prospectus Supplement with
                                            the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments
                                            thereto became effective, at the date of this Agreement and at the Closing Date, the Registration
                                            Statement and any amendments thereto conformed and will conform in all material respects
                                            to the requirements of the Securities Act and did not and will not contain any untrue statement
                                            of a material fact or omit to state any material fact required to be stated therein or necessary
                                            to make the statements therein not misleading; and the Prospectus, the Prospectus Supplement
                                            and any amendments or supplements thereto, at the time the Prospectus Supplement or any amendment
                                            or supplement thereto was issued and at the Closing Date, conformed and will conform in all
                                            material respects to the requirements of the Securities Act and did not and will not contain
                                            an untrue statement of a material fact or omit to state a material fact necessary in order
                                            to make the statements therein, in the light of the circumstances under which they were made,
                                            not misleading. The Company was at the time of the filing of the Registration Statement eligible
                                            to use Form S-3. As of the date of this Agreement, the Company is eligible to use Form&nbsp;S-3
                                            under the Securities Act and meets the transaction requirements as set forth in General Instruction
                                            I.B.1 of Form S-3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalization</U>.
                                            The capitalization of the Company as of the date hereof is as set forth on Schedule 3.1(g),
                                            which Schedule 3.1(g) shall also include the number of shares of Common Stock owned beneficially,
                                            and of record, by Affiliates of the Company as of the date hereof. The Company has an authorized
                                            capitalization as set forth in the SEC Reports. Except as set forth on Schedule 3.1(g) and
                                            as disclosed in the SEC Reports, the Company has not issued any capital stock since its most
                                            recently filed periodic report under the Exchange Act, other than pursuant to the exercise
                                            of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares
                                            of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
                                            or upon the vesting and settlement of restricted stock units under the Company&rsquo;s equity
                                            incentive plans and pursuant to the conversion and/or exercise of Common Stock Equivalents
                                            outstanding as of the date of the most recently filed periodic report under the Exchange
                                            Act. No Person has any right of first refusal, preemptive right, right of participation,
                                            or any similar right to participate in the transactions contemplated by the Transaction Documents.
                                            Except as set forth in&nbsp;<U>Schedule 3.1(g)</U>&nbsp;or as a result of the purchase and
                                            sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe
                                            to, calls or commitments of any character whatsoever relating to, or securities, rights or
                                            obligations convertible into or exercisable or exchangeable for, or giving any Person any
                                            right to subscribe for or acquire, any shares of Common Stock or the capital stock of any
                                            Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
                                            or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common
                                            Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities
                                            will not obligate the Company or any Subsidiary to issue shares of Common Stock or other
                                            securities to any Person (other than the Purchasers). Except as set forth on Schedule 3.1(g),
                                            there are no outstanding securities of the Company or any Subsidiary with any provision that
                                            adjusts the exercise, conversion, exchange or reset price of such security or instrument
                                            upon an issuance of securities by the Company or any Subsidiary. There are no outstanding
                                            securities or instruments of the Company or any Subsidiary that contain any redemption or
                                            similar provisions, and there are no contracts, commitments, understandings or arrangements
                                            by which the Company or any Subsidiary is or may become bound to redeem a security of the
                                            Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom
                                            stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding
                                            shares of capital stock of the Company are duly authorized, validly issued, fully paid and
                                            nonassessable, have been issued in compliance with all federal and state securities laws,
                                            and none of such outstanding shares was issued in violation of any preemptive rights or similar
                                            rights to subscribe for or purchase securities. No further approval or authorization of any
                                            stockholder, the Board of Directors or others is required for the issuance and sale of the
                                            Securities. There are no stockholders agreements, voting agreements or other similar agreements
                                            with respect to the Company&rsquo;s capital stock to which the Company is a party or, to
                                            the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
                                            Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements
                                            and other documents required to be filed by the Company under the Securities Act and the
                                            Exchange Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the one year
                                            preceding the date hereof (or such shorter period as the Company was required by law or regulation
                                            to file such material) (the foregoing materials, including the exhibits thereto and documents
                                            incorporated by reference therein, together with the Prospectus and Prospectus Supplement,
                                            being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely
                                            basis or has received a valid extension of such time of filing and has filed any such SEC
                                            Reports prior to the expiration of any such extension. As of their respective dates, the
                                            SEC Reports complied in all material respects with the requirements of the Securities Act
                                            and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any
                                            untrue statement of a material fact or omitted to state a material fact required to be stated
                                            therein or necessary in order to make the statements therein, in the light of the circumstances
                                            under which they were made, not misleading. The Company has never been an issuer subject
                                            to Rule 144(i) under the Securities Act. The financial statements of the Company, together
                                            with the related notes, included in the SEC Reports comply in all material respects with
                                            applicable accounting requirements and the rules and regulations of the Commission with respect
                                            thereto as in effect at the time of filing. Such financial statements have been prepared
                                            in accordance with United States generally accepted accounting principles applied on a consistent
                                            basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise
                                            specified in such financial statements or the notes thereto and except that unaudited financial
                                            statements may not contain all footnotes required by GAAP, and fairly present in all material
                                            respects the financial position of the Company and its consolidated Subsidiaries as of and
                                            for the dates thereof and the results of operations and cash flows for the periods then ended,
                                            subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Material
                                            Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest
                                            audited financial statements included within the SEC Reports, except as set forth in the
                                            SEC Reports, (i)&nbsp;there has been no event, occurrence or development that has had or
                                            that could reasonably be expected to result in a Material Adverse Effect, (ii)&nbsp;the Company
                                            has not incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables
                                            and accrued expenses incurred in the ordinary course of business consistent with past practice
                                            and (B)&nbsp;liabilities not required to be reflected in the Company&rsquo;s financial statements
                                            pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company
                                            has not altered its method of accounting in any material respect, (iv)&nbsp;the Company has
                                            not declared or made any dividend or distribution of cash or other property to its stockholders
                                            or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
                                            stock and (v)&nbsp;the Company has not issued any equity securities to any executive officer,
                                            director or Affiliate, except pursuant to existing Company stock option or omnibus incentive
                                            plans. The Company does not have pending before the Commission any request for confidential
                                            treatment of information. Except for the issuance of the Securities contemplated by this
                                            Agreement, no event, liability, fact, circumstance, occurrence or development has occurred
                                            or exists or is reasonably expected to occur or exist with respect to the Company or its
                                            Subsidiaries or their respective businesses, prospects, properties, operations, assets or
                                            financial condition that would be required to be disclosed by the Company under applicable
                                            securities laws at the time this representation is made or deemed made that has not been
                                            publicly disclosed at least one (1) Trading Day prior to the date that this representation
                                            is made.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Litigation</U>.
                                            Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation,
                                            Proceeding or investigation pending or, to the knowledge of the Company, threatened against
                                            or affecting the Company, any Subsidiary or any of their respective properties before or
                                            by any court, arbitrator, governmental or administrative agency or regulatory authority (federal,
                                            state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which, if
                                            there were an unfavorable decision, would result in a Material Adverse Effect. None of the
                                            Actions disclosed in the SEC Reports, challenges the legality, validity or enforceability
                                            of any of the Transaction Documents or the Securities. During the last three (3) years prior
                                            to the date of this Agreement, neither the Company nor any Subsidiary, nor any director or
                                            executive officer thereof, is or has been the subject of any Action involving a claim of
                                            violation of or liability under federal or state securities laws or a claim of breach of
                                            fiduciary duty, which would result in a Material Adverse Effect. There has not been, and
                                            to the knowledge of the Company, there is not pending or contemplated, any investigation
                                            by the Commission involving the Company or any current or former director or executive officer
                                            of the Company. The Commission has not issued any stop order or other order suspending the
                                            effectiveness of any registration statement filed by the Company or any Subsidiary under
                                            the Exchange Act or the Securities Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Labor
                                            Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with
                                            respect to any of the employees of the Company, which would reasonably be expected to result
                                            in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
                                            is a member of a union that relates to such employee&rsquo;s relationship with the Company
                                            or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective
                                            bargaining agreement, and the Company and its Subsidiaries believe that their relationships
                                            with their employees are good. To the knowledge of the Company, no executive officer of the
                                            Company or any Subsidiary is, or is now expected to be, in violation of any material term
                                            of any employment contract, confidentiality, disclosure or proprietary information agreement
                                            or non-competition agreement, or any other contract or agreement or any restrictive covenant
                                            in favor of any third-party, and the continued employment of each such executive officer
                                            does not subject the Company or any of its Subsidiaries to any liability with respect to
                                            any of the foregoing matters. The Company and its Subsidiaries are in compliance with all
                                            applicable U.S. federal, state, local and foreign laws and regulations relating to employment
                                            and employment practices, terms and conditions of employment and wages and hours, except
                                            where the failure to be in compliance would not, individually or in the aggregate, reasonably
                                            be expected to have a Material Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance</U>.
                                            Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no
                                            event has occurred that has not been waived that, with notice or lapse of time or both, would
                                            result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary
                                            received notice of a claim that it is in default under or that it is in violation of, any
                                            indenture, loan or credit agreement or any other agreement or instrument to which it is a
                                            party or by which it or any of its properties is bound (whether or not such default or violation
                                            has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator
                                            or other governmental authority or (iii) is or, in the last three (3) years, has been in
                                            violation of any statute, rule, ordinance or regulation of any governmental authority, including
                                            without limitation all foreign, federal, state and local laws relating to taxes, environmental
                                            protection, occupational health and safety, product quality and safety and employment and
                                            labor matters, except in each case as would not have or reasonably be expected to result
                                            in a Material Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Environmental
                                            Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state,
                                            local and foreign laws relating to pollution or protection of human health or the environment
                                            (including ambient air, surface water, groundwater, land surface or subsurface strata), including
                                            laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
                                            contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous
                                            Materials</U>&rdquo;) into the environment, or otherwise relating to the manufacture, processing,
                                            distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
                                            as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
                                            licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered,
                                            promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received
                                            all permits licenses or other approvals required of them under applicable Environmental Laws
                                            to conduct their respective businesses; and (iii) are in compliance with all terms and conditions
                                            of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure
                                            to so comply would be reasonably expected to have, individually or in the aggregate, a Material
                                            Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulatory
                                            Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and
                                            permits issued by the appropriate federal, state, local or foreign regulatory authorities
                                            necessary to conduct their respective businesses as described in the SEC Reports, except
                                            where the failure to possess such permits would not reasonably be expected to result in a
                                            Material Adverse Effect (&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company
                                            nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
                                            of any Material Permit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Title
                                            to Assets</U>. Except as set forth in the SEC Reports, the Company and the Subsidiaries have
                                            good and marketable title in fee simple to all real property owned by them and good and marketable
                                            title in all personal property owned by them that is material to the business of the Company
                                            and the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do
                                            not materially affect the value of such property and do not materially interfere with the
                                            use made and proposed to be made of such property by the Company and the Subsidiaries, (ii)
                                            Liens for the payment of federal, state or other taxes, for which appropriate reserves have
                                            been made therefor in accordance with GAAP and the payment of which is neither delinquent
                                            nor subject to penalties and (iii) such as would not, individually or in the aggregate, result
                                            in a Material Adverse Effect. Any real property and facilities currently held under lease
                                            by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable
                                            leases with which the Company and the Subsidiaries are in compliance in all material respects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual
                                            Property</U>. Except as set forth in the SEC Reports, (i)&nbsp;the Company and each of its
                                            Subsidiaries owns or has adequate rights to use all trademarks, trade names, domain names,
                                            patents, patent rights, mask works, copyrights, technology, know-how (including trade secrets
                                            and other unpatented or unpatentable proprietary or confidential information, systems or
                                            procedures), service marks, trade dress rights and other intellectual property and registrations
                                            and applications for registration for any of the foregoing that are, in each case, material
                                            to the Company (collectively, &ldquo;<U>Intellectual Property</U>&rdquo;) and has such other
                                            rights, licenses, approvals and governmental authorizations, in each case, sufficient to
                                            conduct its business as now conducted and as now proposed to be conducted in all material
                                            respects without any known violation or conflict with any third party Intellectual Property,
                                            and, to the Company&rsquo;s and its Subsidiaries&rsquo; knowledge, there are no rights of
                                            third parties to any such Intellectual Property owned by the Company and its Subsidiaries
                                            and none of the foregoing Intellectual Property rights owned or, licensed by the Company
                                            or any of its Subsidiaries is invalid or unenforceable, (ii)&nbsp;the Company has no knowledge
                                            of any infringement by it or any of its Subsidiaries of Intellectual Property rights of others,
                                            and there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding
                                            or claim by others that the Company and its Subsidiaries infringe or otherwise violate any
                                            Intellectual Property rights of others, where such infringement or violation would have a
                                            Material Adverse Effect, (iii)&nbsp;the Company is not aware of any material infringement,
                                            misappropriation or violation by others of, or conflict by others with rights of the Company
                                            or any of its Subsidiaries with respect to, any Intellectual Property, (iv) there is no suit,
                                            proceeding or claim being made against the Company or any of its Subsidiaries or, to the
                                            knowledge of the Company and its Subsidiaries, any employee of the Company or any of its
                                            Subsidiaries, regarding Intellectual Property, challenging the Company&rsquo;s and its Subsidiaries&rsquo;
                                            rights in or to any such Intellectual Property or alleging other infringement that would
                                            have a Material Adverse Effect and the Company is unaware of any facts which could form a
                                            reasonable basis for any such action, suit, proceeding or claim, (v) to the Company&rsquo;s
                                            knowledge, there is no third-party U.S. patent or published U.S. patent application that
                                            contains claims for which an &ldquo;interference proceeding&rdquo; (as defined in 35 U.S.C.
                                            &sect; 135) has been commenced against any material patent or patent application described
                                            in the Prospectus as being owned by or licensed to the Company and (vi)&nbsp;the Company
                                            and its Subsidiaries have not received any notice of infringement with respect to any patent
                                            or any notice challenging the validity, scope or enforceability of any Intellectual Property
                                            owned by or licensed to the Company or any of its Subsidiaries, in each case the loss of
                                            which patent or Intellectual Property (or loss of rights thereto) would have a Material Adverse
                                            Effect. The Company and its Subsidiaries have taken all reasonable steps necessary to secure
                                            their interests in such Intellectual Property from their employees and contractors (including,
                                            but not limited to, assignments of such Intellectual Property from such employees and contractors)
                                            and to protect the confidentiality of all of their confidential information and trade secrets
                                            and that of third parties in their possession to the extent contractually required to do
                                            so.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance</U>.
                                            The Company and the Subsidiaries are insured by insurers of recognized financial responsibility
                                            against such losses and risks and in such amounts as are prudent and customary in the businesses
                                            in which the Company and the Subsidiaries are engaged, including, but not limited to, directors
                                            and officers insurance coverage in amount deemed prudent by the Company. Neither the Company
                                            nor any Subsidiary has any reason to believe that it will not be able to renew its existing
                                            insurance coverage as and when such coverage expires or to obtain similar coverage from similar
                                            insurers as may be necessary to continue its business at a cost that would not result in
                                            a Material Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transactions
                                            with Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers
                                            or directors of the Company or any Subsidiary and, to the knowledge of the Company, none
                                            of the employees of the Company or any Subsidiary is presently a party to any transaction
                                            with the Company or any Subsidiary (other than for services as employees, officers and directors),
                                            including any contract, agreement or other arrangement providing for the furnishing of services
                                            to or by, providing for rental of real or personal property to or from, providing for the
                                            borrowing of money from or lending of money to or otherwise requiring payments to or from
                                            any officer, director or such employee or, to the knowledge of the Company, any entity in
                                            which any officer, director, or any such employee has a substantial interest or is an officer,
                                            director, trustee, stockholder, member or partner, in each case in excess of $120,000 other
                                            than for (i)&nbsp;payment of salary or consulting fees for services rendered, (ii)&nbsp;reimbursement
                                            for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including
                                            stock option agreements under any stock option plan of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Sarbanes-Oxley;
                                            Internal Accounting Controls</U>. To the Company&rsquo;s knowledge, the Company and the Subsidiaries
                                            are in compliance in all material respects with any and all applicable requirements of the
                                            Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date hereof, and any
                                            and all applicable rules and regulations promulgated by the Commission thereunder that are
                                            effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries
                                            maintain a system of internal accounting controls designed to provide reasonable assurance
                                            that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or
                                            specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation
                                            of financial statements in conformity with GAAP and to maintain asset accountability, (iii)&nbsp;access
                                            to assets is permitted only in accordance with management&rsquo;s general or specific authorization,
                                            and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets
                                            at reasonable intervals and appropriate action is taken with respect to any differences.
                                            The Company has established disclosure controls and procedures (as defined in Exchange Act
                                            Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and
                                            procedures to ensure that material information required to be disclosed by the Company in
                                            the reports it files or submits under the Exchange Act is recorded, processed, summarized
                                            and reported, within the time periods specified in the Commission&rsquo;s rules and forms.
                                            Except as set forth in the SEC Reports, the Company&rsquo;s certifying officers have evaluated
                                            the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries
                                            as of the end of the period covered by the most recently filed periodic report under the
                                            Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented
                                            in its most recently filed periodic report under the Exchange Act the conclusions of the
                                            certifying officers about the effectiveness of the disclosure controls and procedures based
                                            on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been
                                            no changes in the internal control over financial reporting (as such term is defined in the
                                            Exchange Act) of the Company that have materially affected, or are reasonably likely to materially
                                            affect, the internal control over financial reporting of the Company and its Subsidiaries.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
                                            Fees</U>. Except for the fees and expenses of the Placement Agent as set forth in the Placement
                                            Agent Agreement, or as otherwise disclosed in the Prospectus Supplement, no brokerage or
                                            finder&rsquo;s fees or commissions are or will be payable by the Company or any Subsidiary
                                            to any broker, financial advisor or consultant, finder, placement agent, investment banker,
                                            bank or other Person with respect to the transactions contemplated by the Transaction Documents.
                                            The Purchasers shall have no obligation with respect to any fees or with respect to any claims
                                            made by or on behalf of other Persons for fees of a type contemplated in this Section that
                                            may be due in connection with the transactions contemplated by the Transaction Documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment
                                            Company</U>. The Company is not and immediately after receipt of payment for the Securities,
                                            will not be, an &ldquo;investment company&rdquo; within the meaning of the Investment Company
                                            Act of 1940, as amended. The Company shall conduct its business in a manner so that it will
                                            not become an &ldquo;investment company&rdquo; subject to registration under the Investment
                                            Company Act of 1940, as amended.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
                                            Rights</U>. Except as set forth in the SEC Reports, the Registration Statement, the Preliminary
                                            Prospectus and the Prospectus, no Person has any right to cause the Company or any Subsidiary
                                            to effect the registration under the Securities Act of any securities of the Company or any
                                            Subsidiary that has not been satisfied or waived prior to the date hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
                                            and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b)
                                            or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to
                                            its knowledge is likely to have the effect of, terminating the registration of the Common
                                            Stock under the Exchange Act nor has the Company received any notification that the Commission
                                            is contemplating terminating such registration. Except as disclosed in the SEC Reports, the
                                            Company has not, in the 12 months preceding the date hereof, received notice from any Trading
                                            Market on which the Common Stock is or has been listed or quoted to the effect that the Company
                                            is not in compliance with the listing or maintenance requirements of such Trading Market.
                                            Except as set forth in the SEC Reports, the Company is, and has no reason to believe that
                                            it will not in the foreseeable future continue to be, in compliance with all such listing
                                            and maintenance requirements. The Common Stock is currently eligible for electronic transfer
                                            through the Depository Trust Company or another established clearing corporation and the
                                            Company is current in payment of the fees to the Depository Trust Company (or such other
                                            established clearing corporation) in connection with such electronic transfer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Application
                                            of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary
                                            action, if any, in order to render inapplicable any control share acquisition, business combination,
                                            poison pill (including any distribution under a rights agreement) or other similar anti-takeover
                                            provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
                                            or the laws of its state of incorporation that is or could become applicable to the Purchasers
                                            as a result of the Purchasers and the Company fulfilling their obligations or exercising
                                            their rights under the Transaction Documents, including without limitation as a result of
                                            the Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the
                                            Securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Disclosure</U>.
                                            Except with respect to the material terms and conditions of the transactions contemplated
                                            by the Transaction Documents and the representations made in Section 3.1(i), the Company
                                            confirms that neither it nor any other Person acting on its behalf has provided any of the
                                            Purchasers or their agents or counsel with any information that it believes constitutes or
                                            might constitute material, non-public information which is not otherwise disclosed in the
                                            Prospectus Supplement. The Company understands and confirms that the Purchasers will rely
                                            on the foregoing representation in effecting transactions in securities of the Company. All
                                            of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the
                                            Company and its Subsidiaries, their respective businesses and the transactions contemplated
                                            hereby, including the Disclosure Schedules to this Agreement, when taken together as a whole,
                                            is true and correct and does not contain any untrue statement of a material fact or omit
                                            to state any material fact necessary in order to make the statements made therein, in the
                                            light of the circumstances under which they were made, not misleading. The press releases
                                            disseminated by the Company during the twelve months preceding the date of this Agreement
                                            taken as a whole do not contain any untrue statement of a material fact or omit to state
                                            a material fact required to be stated therein or necessary in order to make the statements
                                            therein, in the light of the circumstances under which they were made and when made, not
                                            misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
                                            or warranties with respect to the transactions contemplated hereby other than those specifically
                                            set forth in Section 3.2 hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and
                                            warranties set forth in Section 3.2, neither the Company, nor any of its controlled Affiliates,
                                            nor any Person acting on its or their behalf has, directly or indirectly, made any offers
                                            or sales of any security or solicited any offers to buy any security, under circumstances
                                            that would cause this offering of the Securities to be integrated with prior offerings by
                                            the Company for purposes of (i)&nbsp;the Securities Act which would require the registration
                                            of any such securities under the Securities Act, or (ii)&nbsp;any applicable shareholder
                                            approval provisions of any Trading Market on which any of the securities of the Company are
                                            listed or designated.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indebtedness</U>.
                                            The SEC Reports set forth as of the date hereof all outstanding secured and unsecured Indebtedness
                                            of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments.
                                            For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x)&nbsp;any
                                            liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts
                                            payable or accrued payroll liabilities incurred in the ordinary course of business), (y)&nbsp;all
                                            guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
                                            whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance
                                            sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments
                                            for deposit or collection or similar transactions in the ordinary course of business; and
                                            (z)&nbsp;the present value of any lease payments in excess of $100,000 due under leases required
                                            to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default
                                            with respect to any Indebtedness, which defaults, individually or in the aggregate, would
                                            have a Material Adverse Effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Tax
                                            Status</U>. Except for matters that would not, individually or in the aggregate, have or
                                            reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries
                                            each (i)&nbsp;has made or filed all material United States federal, state and local income
                                            and all foreign income and franchise tax returns, reports and declarations required by any
                                            jurisdiction to which it is subject, (ii)&nbsp;has paid all material taxes and other governmental
                                            assessments and charges that are material in amount, shown or determined to be due on such
                                            returns, reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably
                                            adequate for the payment of all material taxes for periods subsequent to the periods to which
                                            such returns, reports or declarations apply. There are no unpaid taxes in any material amount
                                            claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company
                                            or of any Subsidiary know of no basis for any such claim.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Foreign
                                            Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the
                                            Company or any Subsidiary, any agent or other person acting on behalf of the Company or any
                                            Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions,
                                            gifts, entertainment or other unlawful expenses related to foreign or domestic political
                                            activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials
                                            or employees or to any foreign or domestic political parties or campaigns from corporate
                                            funds, (iii)&nbsp;failed to disclose fully any contribution made by the Company or any Subsidiary
                                            (or made by any person acting on its behalf of which the Company is aware) which is in violation
                                            of law or (iv)&nbsp;violated in any material respect any provision of FCPA.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Accountants</U>.
                                            The Company&rsquo;s accounting firm is MaloneBailey, LLP. To the knowledge and belief of
                                            the Company, such accounting firm (i)&nbsp;is a registered public accounting firm as required
                                            by the Exchange Act and (ii)&nbsp;has expressed its opinion with respect to the financial
                                            statements to be included in the Company&rsquo;s Annual Report for the fiscal year ended
                                            December 31, 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Acknowledgment
                                            Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees
                                            that, to its knowledge, each of the Purchasers is acting solely in the capacity of an arm&rsquo;s
                                            length purchaser with respect to the Transaction Documents and the transactions contemplated
                                            thereby. The Company further acknowledges that, to its knowledge, no Purchaser is acting
                                            as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
                                            to the Transaction Documents and the transactions contemplated thereby and any advice given
                                            by any Purchaser or any of their respective representatives or agents in connection with
                                            the Transaction Documents and the transactions contemplated thereby is merely incidental
                                            to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each
                                            Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction
                                            Documents has been based solely on the independent evaluation of the transactions contemplated
                                            hereby by the Company and its representatives.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Acknowledgment
                                            Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere
                                            herein to the contrary notwithstanding (except for Sections&nbsp;3.2(g) and 4.13 hereof),
                                            it is understood and acknowledged by the Company that: (i) none of the Purchasers has agreed
                                            to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo;
                                            securities based on securities issued by the Company or to hold the Securities for any specified
                                            term, (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically
                                            including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions, before
                                            or after the closing of this or future private placement transactions, may negatively impact
                                            the market price of the Company&rsquo;s publicly-traded securities, (iii)&nbsp;any Purchaser,
                                            and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser
                                            is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in
                                            the Common Stock and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation
                                            with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
                                            transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers
                                            may engage in legal hedging activities at various times during the period that the Securities
                                            are outstanding and (z)&nbsp;such hedging activities (if any) could reduce the value of the
                                            existing stockholders&rsquo; equity interests in the Company at and after the time that the
                                            hedging activities are being conducted. The Company acknowledges that such aforementioned
                                            hedging activities do not constitute a breach of any of the Transaction Documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Regulation
                                            M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has,
                                            (i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the
                                            stabilization or manipulation of the price of any security of the Company to facilitate the
                                            sale or resale of any of the Securities, (ii)&nbsp;sold, bid for, purchased, or paid any
                                            compensation for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed
                                            to pay to any Person any compensation for soliciting another to purchase any other securities
                                            of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the
                                            Company&rsquo;s placement agent in connection with the placement of the Securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
                                            Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock
                                            option plan was granted (i)&nbsp;in accordance with the terms of the Company&rsquo;s stock
                                            option plan and (ii)&nbsp;with an exercise price at least equal to the fair market value
                                            of the Common Stock on the date such stock option would be considered granted under GAAP
                                            and applicable law. No stock option granted under the Company&rsquo;s stock option plan has
                                            been backdated. The Company has not knowingly granted, and there is no and has been no Company
                                            policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate
                                            the grant of stock options with, the release or other public announcement of material information
                                            regarding the Company or its Subsidiaries or their financial results or prospects.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Office
                                            of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s
                                            knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary
                                            is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
                                            of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>U.S.
                                            Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real
                                            property holding corporation within the meaning of Section 897 of the Internal Revenue Code
                                            of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Bank
                                            Holding Company Act</U>. Neither the Company nor any of its Subsidiaries is subject to the
                                            Bank Holding Company Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation
                                            by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal Reserve</U>&rdquo;).
                                            Neither the Company nor any of its Subsidiaries owns or controls, directly or indirectly,
                                            five percent (5%) or more of the outstanding shares of any class of voting securities or
                                            twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject
                                            to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its
                                            Subsidiaries exercises a controlling influence over the management or policies of a bank
                                            or any entity that is subject to the BHCA and to regulation by the Federal Reserve.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Money
                                            Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted
                                            at all times in compliance in all material respects with applicable financial record-keeping
                                            and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
                                            as amended, applicable money laundering statutes and applicable rules and regulations thereunder
                                            (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding
                                            by or before any court or governmental agency, authority or body or any arbitrator involving
                                            the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to
                                            the knowledge of the Company or any Subsidiary, threatened.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Cybersecurity</U>.
                                            To the knowledge of the Company, except as would not, individually or in the aggregate, have
                                            a Material Adverse Effect (i)(x)&nbsp;there has been no security breach or other compromise
                                            of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology
                                            and computer systems, networks, hardware, software, data (including the data of its respective
                                            customers, employees, suppliers, vendors and any third party data maintained by or on behalf
                                            of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
                                            and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has no knowledge
                                            of any event or condition that would reasonably be expected to result in, any security breach
                                            or other compromise to its IT Systems and Data; (ii)&nbsp;the Company and the Subsidiaries
                                            are presently in compliance with all applicable laws or statutes and all judgments, orders,
                                            rules and regulations of any court or arbitrator or governmental or regulatory authority,
                                            internal policies and contractual obligations relating to the privacy and security of IT
                                            Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
                                            access, misappropriation or modification, except as would not, individually or in the aggregate,
                                            have a Material Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented
                                            and maintained commercially reasonable safeguards to maintain and protect its material confidential
                                            information and the integrity, continuous operation, redundancy and security of all IT Systems
                                            and Data; and (iv)&nbsp;the Company and the Subsidiaries have implemented backup and disaster
                                            recovery technology consistent with commercially reasonable industry standards and practices.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance
                                            with Laws</U>. Each of the Company and its Subsidiaries: (A)&nbsp;is and at all times has
                                            been in compliance with all statutes, rules, or regulations applicable to the ownership,
                                            testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
                                            promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured
                                            or distributed by the Company or its Subsidiaries (&ldquo;<U>Applicable Laws</U>&rdquo;),
                                            except as would not, individually or in the aggregate, reasonably be expected to result in
                                            a Material Adverse Effect; (B)&nbsp;has not received any U.S. Food and Drug Administration
                                            (&ldquo;<U>FDA</U>&rdquo;) Form 483, written notice of adverse finding, warning letter, untitled
                                            letter or other correspondence or written notice from the FDA or any other Governmental Authority
                                            alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates,
                                            approvals, clearances, authorizations, permits and supplements or amendments thereto required
                                            by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;) except for a noncompliance
                                            that would not reasonably be expected to have a Material Adverse Effect; (C)&nbsp;possesses
                                            all material Authorizations and such Authorizations are valid and in full force and effect
                                            and are not in violation of any term of any such Authorizations except for a violation that
                                            would not reasonably be expected to have a Material Adverse Effect; (D)&nbsp;has not received
                                            written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
                                            arbitration or other action from any Governmental Authority or third party alleging that
                                            any product operation or activity is in violation of any Applicable Laws or Authorizations
                                            and has no knowledge that any such Governmental Authority or third party is considering any
                                            such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has
                                            not received written notice that any Governmental Authority has taken, is taking or intends
                                            to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge
                                            that any such Governmental Authority is considering such action; (F)&nbsp;has filed, obtained,
                                            maintained or submitted all material reports, documents, forms, written notices, applications,
                                            records, claims, submissions and supplements or amendments as required by any Applicable
                                            Laws or Authorizations and that all such reports, documents, forms, written notices, applications,
                                            records, claims, submissions and supplements or amendments were complete and correct in all
                                            material respects on the date filed (or were corrected or supplemented by a subsequent submission);
                                            and (G)&nbsp;has not, either voluntarily or involuntarily, initiated, conducted, or issued
                                            or caused to be initiated, conducted or issued, any recall which had or is expected to have
                                            a Material Adverse Effect, market withdrawal or replacement, safety alert, post-sale warning,
                                            &ldquo;dear healthcare provider&rdquo; letter, or other written notice or action relating
                                            to the alleged lack of safety or efficacy of any product or any alleged product defect or
                                            violation and, to the Company&rsquo;s knowledge, no third party has initiated, conducted
                                            or intends to initiate any such notice or action.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
                                            and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser,
                                            hereby represents and warrants as of the date hereof and as of the Closing Date to the Company
                                            as follows (unless as of a specific date therein, in which case they shall be accurate as
                                            of such date):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organization;
                                            Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed,
                                            validly existing and in good standing under the laws of the jurisdiction of its incorporation
                                            or formation with full right, corporate, partnership, limited liability company or similar
                                            power and authority to enter into and to consummate the transactions contemplated by the
                                            Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
                                            The execution and delivery of the Transaction Documents and performance by such Purchaser
                                            of the transactions contemplated by the Transaction Documents have been duly authorized by
                                            all necessary corporate, partnership, limited liability company or similar action, as applicable,
                                            on the part of such Purchaser. Each Transaction Document to which it is a party has been
                                            duly executed by such Purchaser, and when delivered by such Purchaser in accordance with
                                            the terms hereof, will constitute the valid and legally binding obligation of such Purchaser,
                                            enforceable against it in accordance with its terms, except (i)&nbsp;as limited by general
                                            equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
                                            other laws of general application affecting enforcement of creditors&rsquo; rights generally,
                                            (ii)&nbsp;as limited by laws relating to the availability of specific performance, injunctive
                                            relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution
                                            provisions may be limited by applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Conflicts</U>. The execution, delivery and performance by the Purchaser of this Agreement,
                                            the other Transaction Documents to which it is a party, and the consummation by the Purchaser
                                            of the transactions contemplated hereby and thereby will not (i)&nbsp;result in a violation
                                            of the organizational documents of the Purchaser, (ii)&nbsp;conflict with, or constitute
                                            a default (or an event which with notice or lapse of time or both would become a default)
                                            under, or give to others any rights of termination, amendment, acceleration or cancellation
                                            of, any agreement, indenture or instrument to which the Purchaser is a party, or (iii)&nbsp;result
                                            in a violation by such Purchaser of any law, rule, regulation, order, judgment or decree
                                            (including federal and state securities laws) applicable to such Purchaser, except in the
                                            case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations
                                            which would not, individually or in the aggregate, reasonably be expected to have a material
                                            adverse effect on the ability of the Purchaser to perform its obligations under the Transaction
                                            Documents to which it is a party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Understandings
                                            or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own
                                            account, for investment purposes only, and has no direct or indirect arrangement or understandings
                                            with any other persons to distribute or regarding the distribution of such Securities (this
                                            representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities
                                            pursuant to the Registration Statement or otherwise in compliance with applicable federal
                                            and state securities laws).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Experience
                                            of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives,
                                            has such knowledge, sophistication and experience in business and financial matters so as
                                            to be capable of evaluating the merits and risks of the prospective investment in the Securities,
                                            and has so evaluated the merits and risks of its decision to purchase Securities pursuant
                                            to the Transaction Documents. The Purchaser understands that nothing in this Agreement or
                                            any other materials presented by or on behalf of the Company to the Purchaser in connection
                                            with the purchase of the Securities constitutes legal, tax or investment advice. The Purchaser
                                            has consulted such legal, tax and investment advisors as it, in its sole discretion, has
                                            deemed necessary or appropriate in connection with its purchase of the Securities. The Purchaser
                                            understands that the Placement Agent has acted solely as the agent of the Company in this
                                            placement of the Securities and the Purchaser has not relied on the business or legal advice
                                            of the Placement Agent or any of their agents, counsel or Affiliates in making its investment
                                            decision hereunder, and confirms that none of such Persons has made any representations or
                                            warranties to the Purchaser in connection with the transactions contemplated by the Transaction
                                            Documents. Such Purchaser is able to bear the economic risk of an investment in the Securities
                                            and, at the present time, is able to afford a complete loss of such investment.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Access
                                            to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review
                                            the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports,
                                            the Registration Statement and Prospectus and has been afforded (i)&nbsp;the opportunity
                                            to ask such questions as it has deemed necessary of, and to receive answers from, representatives
                                            of the Company concerning the terms and conditions of the offering of the Securities and
                                            the merits and risks of investing in the Securities; (ii)&nbsp;access to information about
                                            the Company and its financial condition, results of operations, business, properties, management
                                            and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity
                                            to obtain such additional information that the Company possesses or can acquire without unreasonable
                                            effort or expense that is necessary to make an informed investment decision with respect
                                            to the investment. Such Purchaser acknowledges and agrees that neither the Placement Agent
                                            nor any Affiliate of the Placement Agent has provided such Purchaser with any information
                                            or advice with respect to the Securities nor is such information or advice necessary or desired.
                                            Neither the Placement Agent nor any Affiliate has made or makes any representation as to
                                            the Company or the quality of the Securities and the Placement Agent and any Affiliate may
                                            have acquired non-public information with respect to the Company which such Purchaser agrees
                                            need not be provided to it. In connection with the issuance of the Securities to such Purchaser,
                                            neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or
                                            fiduciary to such Purchaser. The Purchaser understands and acknowledges that his, her or
                                            its purchase of the Securities is a speculative investment that involves a high degree of
                                            risk and the potential loss of their entire investment and has carefully read and considered
                                            the matters and Risk factors set forth in the SEC Reports.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
                                            Transactions and Confidentiality</U>. Other than consummating the transactions contemplated
                                            hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to
                                            any understanding with such Purchaser, directly or indirectly executed any purchases or sales,
                                            including Short Sales, of the securities of the Company during the period commencing as of
                                            the time that such Purchaser first received a term sheet (written or oral) from the Company
                                            or any other Person representing the Company setting forth the material terms of the transactions
                                            contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
                                            the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
                                            separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and
                                            the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
                                            managers managing other portions of such Purchaser&rsquo;s assets, the representation set
                                            forth above shall only apply with respect to the portion of assets managed by the portfolio
                                            manager that made the investment decision to purchase the Securities covered by this Agreement.
                                            Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives,
                                            including, without limitation, its officers, directors, partners, legal and other advisors,
                                            employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all
                                            disclosures made to it in connection with this transaction (including the existence and terms
                                            of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing
                                            contained herein shall constitute a representation or warranty, or preclude any actions,
                                            with respect to locating or borrowing shares in order to effect Short Sales or similar transactions
                                            in the future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Voting Agreements</U>. The Purchaser is not a party to any agreement or arrangement, whether
                                            written or oral, between the Purchaser and any other Purchaser and any of the Company&rsquo;s
                                            stockholders as of the date hereof, regulating the management of the Company, the stockholders&rsquo;
                                            rights in the Company, the transfer of shares in the Company, including any voting agreements,
                                            stockholder agreements or any other similar agreement, even if its title is different or
                                            has any other relations or agreements with any of the Company&rsquo;s stockholders, directors
                                            or officers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Brokers</U>.
                                            Except as set forth in the Prospectus, no agent, broker, investment banker, person or firm
                                            acting in a similar capacity on behalf of or under the authority of the Purchaser is or will
                                            be entitled to any broker&rsquo;s or finder&rsquo;s fee or any other commission or similar
                                            fee, directly or indirectly, for which the Company or any of its Affiliates after the Closing
                                            could have any liabilities in connection with this Agreement, any of the transactions contemplated
                                            by this Agreement, or on account of any action taken by the Purchaser in connection with
                                            the transactions contemplated by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Independent
                                            Advice</U>. Each Purchaser understands that nothing in this Agreement or any other materials
                                            presented by or on behalf of the Company to the Purchaser in connection with the purchase
                                            of the Securities constitutes legal, tax or investment advice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purchaser
                                            Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the
                                            date hereof it is, and on each date on which it exercises any Pre-Funded Warrants, it will
                                            be either (i) an &ldquo;accredited investor&rdquo; as defined in Rule&nbsp;501(a)(1), (a)(2),
                                            (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act, or (ii) a &ldquo;qualified
                                            institutional buyer&rdquo; as defined in Rule 144A(a) under the Securities Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Hart-Scott-Rodino
                                            Act</U>. Each Purchaser has determined, in good faith and in accordance with 16 C.F.R. &sect;
                                            801.10(c)(3), that the fair market value of the voting securities of the Company already
                                            held by such Purchaser, together with the purchase price of the Shares to be acquired by
                                            such Purchaser, is not greater than $119.5 million.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document, or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
4. OTHER AGREEMENTS OF THE PARTIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legends</U>.
                                            The Shares and Warrant Shares shall be issued free of legends.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Furnishing
                                            of Information; Public Information</U>. Until the earlier of the date the Purchaser owns
                                            no Shares or one year after the Closing Date, the Company covenants to use commercially reasonable
                                            efforts to maintain the registration of the Common Stock under Section 12(b) or 12(g) of
                                            the Exchange Act and to timely file (or obtain extensions in respect thereof and file within
                                            the applicable grace period) all reports required to be filed by the Company after the date
                                            hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
                                            requirements of the Exchange Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Integration</U>.
                                            The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate
                                            in respect of any security (as defined in Section 2 of the Securities Act) that would be
                                            integrated with the offer or sale of the Securities for purposes of the rules and regulations
                                            of any Trading Market such that it would require shareholder approval prior to the closing
                                            of such other transaction unless shareholder approval is obtained before the closing of such
                                            subsequent transaction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Securities
                                            Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press
                                            release disclosing the material terms of the transactions contemplated hereby, and (b) file
                                            a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with
                                            the Commission within the time required by the Exchange Act. From and after the issuance
                                            of such press release, the Company represents to the Purchasers that it shall have publicly
                                            disclosed all material, non-public information delivered to any of the Purchasers by the
                                            Company or any of its Subsidiaries, or any of their authorized officers, directors, employees
                                            or agents in connection with the transactions contemplated by the Transaction Documents.
                                            In addition, effective upon the issuance of such press release, the Company acknowledges
                                            and agrees that any and all confidentiality or similar obligations under any agreement, whether
                                            written or oral, between the Company, any of its Subsidiaries or any of their respective
                                            officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers
                                            or any of their Affiliates on the other hand, shall terminate. The Company and each Purchaser
                                            shall consult with each other in issuing any other press releases with respect to the transactions
                                            contemplated hereby, and neither the Company nor any Purchaser shall issue any such press
                                            release nor otherwise make any such public statement without the prior consent of the Company,
                                            with respect to any press release of any Purchaser, or without the prior consent of each
                                            Purchaser, with respect to any press release of the Company, which consent shall not unreasonably
                                            be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
                                            party shall promptly provide the other party with prior notice of such public statement or
                                            communication. Notwithstanding the foregoing, the Company shall not publicly disclose the
                                            name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
                                            or any regulatory agency or Trading Market, without the prior written consent of such Purchaser
                                            (not to be unreasonably withheld), except (a) as required by federal securities law in connection
                                            with (i) any registration statement contemplated by this Agreement and (ii) the filing of
                                            final Transaction Documents with the Commission and (b) to the extent such disclosure is
                                            required by law or Trading Market regulations, in which case the Company shall provide the
                                            Purchasers with prior notice of such disclosure permitted under this clause (b).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Shareholder
                                            Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of
                                            the Company, any other Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo;
                                            under any control share acquisition, business combination, poison pill (including any distribution
                                            under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter
                                            adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of
                                            any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
                                            or under any other agreement between the Company and the Purchasers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Non-Public
                                            Information</U>. Except with respect to the material terms and conditions of the transactions
                                            contemplated by the Transaction Documents, which shall be disclosed pursuant to Section 4.4,
                                            the Company covenants and agrees that neither it, nor any other Person acting on its behalf
                                            will provide any Purchaser or its agents or counsel with any information that constitutes,
                                            or the Company reasonably believes constitutes, material non-public information, unless prior
                                            thereto such Purchaser shall have consented to the receipt of such information and agreed
                                            with the Company to keep such information confidential. The Company understands and confirms
                                            that each Purchaser shall be relying on the foregoing covenant in effecting transactions
                                            in securities of the Company. To the extent that the Company delivers any material, non-public
                                            information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants
                                            and agrees that such Purchaser shall not have any duty of confidentiality to the Company,
                                            any of its Subsidiaries, or any of their respective officers, directors, agents, employees
                                            or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective
                                            officers, directors, agents, employees or Affiliates not to trade on the basis of, such material,
                                            non-public information, provided that the Purchaser shall remain subject to applicable law.
                                            To the extent that any notice provided pursuant to any Transaction Document constitutes,
                                            or contains, material, non-public information regarding the Company or any Subsidiaries,
                                            the Company shall promptly with the delivery of such notice file such material non-public
                                            information with the Commission pursuant to a Current Report on Form 8-K. The Company understands
                                            and confirms that each Purchaser shall be relying on the foregoing covenant in effecting
                                            transactions in securities of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use
                                            of Proceeds</U>. Except as set forth in the SEC Reports, the Company shall use the net proceeds
                                            from the sale of the Securities hereunder for working capital purposes and shall not use
                                            such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other
                                            than payment of trade payables in the ordinary course of the Company&rsquo;s business and
                                            prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents,
                                            (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC
                                            regulations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification
                                            of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify
                                            and hold each Purchaser and its directors, officers, shareholders, members, partners, employees
                                            and agents (and any other Persons with a functionally equivalent role of a Person holding
                                            such titles notwithstanding a lack of such title or any other title), each Person who controls
                                            such Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of
                                            the Exchange Act), and the directors, officers, shareholders, agents, members, partners or
                                            employees (and any other Persons with a functionally equivalent role of a Person holding
                                            such titles notwithstanding a lack of such title or any other title) of such controlling
                                            persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses,
                                            liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
                                            judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees
                                            and costs of investigation that any such Purchaser Party may suffer or incur as a result
                                            of or relating to (a) any breach of any of the representations, warranties, covenants or
                                            agreements made by the Company in this Agreement or in the other Transaction Documents or
                                            (b) any action instituted against the Purchaser Parties in any capacity, or any of them or
                                            their respective Affiliates, by any stockholder of the Company who is not an Affiliate of
                                            such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
                                            Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s
                                            representations, warranties or covenants under the Transaction Documents or any agreements
                                            or understandings such Purchaser Party may have with any such stockholder or any violations
                                            by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser
                                            Party which is finally judicially determined to constitute fraud, gross negligence or willful
                                            misconduct). If any action shall be brought against any Purchaser Party in respect of which
                                            indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify
                                            the Company in writing, and the Company shall have the right to assume the defense thereof
                                            with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser
                                            Party shall have the right to employ separate counsel in any such action and participate
                                            in the defense thereof, but the fees and expenses of such counsel shall be at the expense
                                            of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
                                            authorized by the Company in writing, (ii) the Company has failed after a reasonable period
                                            of time to assume such defense and to employ counsel or (iii) in such action there is, in
                                            the reasonable opinion of counsel, a material conflict on any material issue between the
                                            position of the Company and the position of such Purchaser Party, in which case the Company
                                            shall be responsible for the reasonable fees and expenses of no more than one such separate
                                            counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for
                                            any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent,
                                            which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the
                                            extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s
                                            breach of any of the representations, warranties, covenants or agreements made by such Purchaser
                                            Party in this Agreement or in the other Transaction Documents or the fraud, gross negligence
                                            or willful misconduct of such Purchaser Party as determined by a final, non-appealable judgment
                                            of a court of competent jurisdiction. The indemnification required by this Section 4.8 shall
                                            be made by periodic payments of the amount thereof during the course of the investigation
                                            or defense, as and when bills are received or are incurred; provided, however, that if it
                                            is subsequently determined by a final, non-appealable judgment of a court of competent jurisdiction
                                            that a Purchaser Party was not entitled to receive such periodic payments, such Purchaser
                                            Party shall, within five (5) Business Days of such judgment, return such payments to the
                                            Company. The indemnity agreements contained herein shall be in addition to any cause of action
                                            or similar right of any Purchaser Party against the Company or others and any liabilities
                                            the Company may be subject to pursuant to law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservation
                                            of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall
                                            continue to reserve and keep available at all times, free of preemptive rights, a sufficient
                                            number of shares of Common Stock for the purpose of enabling the Company to issue the Shares
                                            and Warrant Shares pursuant to this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
                                            of Common Stock</U>. The Company hereby agrees to use commercially reasonable best efforts
                                            to maintain the listing or quotation of the Common Stock on the Trading Market on which it
                                            is currently listed, and concurrently with the Closing, the Company shall apply to list or
                                            quote all of the Shares on such Trading Market and promptly secure the listing of all of
                                            the Shares on such Trading Market prior to Closing. The Company further agrees, if the Company
                                            applies to have the Common Stock traded on any other Trading Market, it will then include
                                            in such application all of the Shares and will take such other action as is necessary to
                                            cause all of the Shares to be listed or quoted on such other Trading Market as promptly as
                                            possible. The Company will then take all action reasonably necessary to continue the listing
                                            and trading of its Common Stock on a Trading Market and will comply in all respects with
                                            the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of
                                            the Trading Market. For so long as the Company maintains a listing or quotation of the Common
                                            Stock on a Trading Market, the Company agrees to use commercially reasonable efforts to maintain
                                            the eligibility of the Common Stock for electronic transfer through the Depository Trust
                                            Company or another established clearing corporation, including, without limitation, by timely
                                            payment of fees to the Depository Trust Company or such other established clearing corporation
                                            in connection with such electronic transfer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent
                                            Equity Sales</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
                                            the date hereof until ninety (90) days following the Closing Date, neither the Company nor
                                            any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance
                                            or proposed issuance of any Common Stock or Common Stock Equivalents or (ii) file any registration
                                            statement or any amendment or supplement thereto, other than the Prospectus Supplement, any
                                            necessary filing for an Exempt Issuance under applicable law, a registration statement on
                                            Form S-8 with respect to a shareholder approved equity incentive plan or file any amendment
                                            or supplement to any existing registration statement solely for the purpose of revising any
                                            required disclosure in such registration statement and not for the purpose of increasing
                                            the offering size pursuant to such registration statement; provided, however, that the foregoing
                                            shall not prohibit the Company from conducting an offering of shares of Common Stock (and
                                            not Common Stock Equivalents) at a price per share equal to or greater than $2.00 (as adjusted
                                            for any stock splits, stock dividends, stock combinations, recapitalizations or other similar
                                            transactions occurring after the date hereof) or filing any registration statement or amendment
                                            or supplement thereto in connection with any such offering; provided, further, that the Company
                                            shall offer the Placement Agent the opportunity to participate in any such offering as a
                                            co-placement agent on customary terms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
                                            the date hereof until one hundred and eighty (180) days after the Closing Date, the Company
                                            shall be prohibited from effecting or entering into an agreement to effect any issuance by
                                            the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a
                                            combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate
                                            Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells any debt
                                            or equity securities that are convertible into, exchangeable or exercisable for, or include
                                            the right to receive additional shares of Common Stock either (A) at a conversion price,
                                            exercise price or exchange rate or other price that is based upon and/or varies with the
                                            trading prices of or quotations for the shares of Common Stock at any time after the initial
                                            issuance of such debt or equity securities, or (B) with a conversion, exercise or exchange
                                            price that is subject to being reset at some future date after the initial issuance of such
                                            debt or equity security or upon the occurrence of specified or contingent events directly
                                            or indirectly related to the business of the Company or the market for the Common Stock or
                                            (ii) enters into, or effects a transaction under, any agreement, including, but not limited
                                            to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company
                                            may issue securities at a future determined price regardless of whether shares pursuant to
                                            such agreement have actually been issued and regardless of whether such agreement is subsequently
                                            canceled; provided, however, that the issuance of shares of Common Stock in an &ldquo;at-the-market&rdquo;
                                            offering shall not be deemed a Variable Rate Transaction after thirty (30) days after the
                                            Closing Date. Any Purchaser shall be entitled to obtain injunctive relief against the Company
                                            to preclude any such issuance, which remedy shall be in addition to any right to collect
                                            damages.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
                                            the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Equal
                                            Treatment of Purchasers</U>. No consideration (including any modification of any Transaction
                                            Document) shall be offered or paid to any Person to amend or consent to a waiver or modification
                                            of any provision of the Transaction Documents unless the same consideration is also offered
                                            to all of the parties to the Transaction Documents. For clarification purposes, this provision
                                            constitutes a separate right granted to each Purchaser by the Company and negotiated separately
                                            by each Purchaser, and is intended for the Company to treat the Purchasers as a class and
                                            shall not in any way be construed as the Purchasers acting in concert or as a group with
                                            respect to the purchase, disposition or voting of Securities or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Certain
                                            Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the
                                            other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf or pursuant
                                            to any understanding with it will execute any purchases or sales, including Short Sales,
                                            of any of the Company&rsquo;s securities during the period commencing with the execution
                                            of this Agreement and ending at such time that the transactions contemplated by this Agreement
                                            are first publicly announced pursuant to the initial press release as described in Section
                                            4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
                                            until such time as the transactions contemplated by this Agreement are publicly disclosed
                                            by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser
                                            will maintain the confidentiality of the existence and terms of this transaction and the
                                            information included in the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding
                                            anything contained in this Agreement to the contrary, the Company expressly acknowledges
                                            and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
                                            it will not engage in effecting transactions in any securities of the Company after the time
                                            that the transactions contemplated by this Agreement are first publicly announced pursuant
                                            to the initial press release as described in Section 4.4, (ii)&nbsp;no Purchaser shall be
                                            restricted or prohibited from effecting any transactions in any securities of the Company
                                            in accordance with applicable securities laws from and after the time that the transactions
                                            contemplated by this Agreement are first publicly announced pursuant to the initial press
                                            release as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality
                                            or duty not to trade in the securities of the Company to the Company or its Subsidiaries
                                            after the issuance of the initial press release as described in Section 4.4. Notwithstanding
                                            the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby
                                            separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and
                                            the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
                                            managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth
                                            above shall only apply with respect to the portion of assets managed by the portfolio manager
                                            that made the investment decision to purchase the Securities covered by this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise
                                            Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality
                                            of the procedures required of the Purchasers in order to exercise the Warrants. No additional
                                            legal opinion, other information or instructions shall be required of the Purchasers to exercise
                                            their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise
                                            shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
                                            of any Notice of Exercise form be required in order to exercise the Warrants. The Company
                                            shall honor exercises of the Warrants and shall deliver shares of Common Stock and/or Warrant
                                            Shares in accordance with the terms, conditions and time periods set forth in the Transaction
                                            Documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reservations
                                            of Shares</U>. As of the date hereof, the Company has reserved and the Company shall continue
                                            to reserve and keep available at all times, free of preemptive rights, a sufficient number
                                            of shares of Common Stock for the purpose of enabling the Company to issue shares of Common
                                            Stock pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Lock-Up
                                            Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of
                                            any of the Lock-Up Agreements without the prior written consent of the Placement Agent (not
                                            to be unreasonably withheld, conditioned or delayed), except to extend the term of the lock-up
                                            period, and shall use commercially reasonable efforts to enforce the provisions of each Lock-Up
                                            Agreement in accordance with its terms. If any party to a Lock-Up Agreement breaches any
                                            provision of a Lock-Up Agreement, the Company shall promptly use its commercially reasonable
                                            efforts to seek specific performance of the terms of such Lock-Up Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ARTICLE
5. MISCELLANEOUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination</U>.
                                            This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations
                                            hereunder only and without any effect whatsoever on the obligations between the Company and
                                            the other Purchasers, by written notice to the other parties, if the Closing has not been
                                            consummated on or before the fifth (5th) Trading Day following the date hereof; provided,
                                            however, that no such termination will affect the right of any party to sue for any breach
                                            by any other party (or parties).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Fees
                                            and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary,
                                            each party shall pay the fees and expenses of its advisers, counsel, accountants and other
                                            experts, if any, and all other expenses incurred by such party incident to the negotiation,
                                            preparation, execution, delivery and performance of this Agreement. The Company shall pay
                                            all Transfer Agent fees (including, without limitation, any fees required for same-day processing
                                            of any instruction letter delivered by the Company and any exercise notice delivered by a
                                            Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery
                                            of any Securities to the Purchasers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire
                                            Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto,
                                            contain the entire understanding of the parties with respect to the subject matter hereof
                                            and thereof and supersede all prior agreements and understandings, oral or written, with
                                            respect to such matters, which the parties acknowledge have been merged into such documents,
                                            exhibits and schedules.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U>.
                                            Any and all notices or other communications or deliveries required or permitted to be provided
                                            hereunder shall be in writing and shall be deemed given and effective on the earliest of:
                                            (a) the time of transmission, if such notice or communication is delivered via facsimile
                                            at the facsimile number or email attachment at the email address as set forth on the signature
                                            pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)
                                            the next Trading Day after the time of transmission, if such notice or communication is delivered
                                            via facsimile at the facsimile number or email attachment at the email address as set forth
                                            on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30
                                            p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day following
                                            the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon
                                            actual receipt by the party to whom such notice is required to be given. The address for
                                            such notices and communications shall be as set forth on the signature pages attached hereto.
                                            To the extent that any notice provided pursuant to any Transaction Document constitutes,
                                            or contains material, non-public information regarding the Company or any of the Subsidiaries,
                                            the Company shall promptly with the delivery of such notice file such material non-public
                                            information with the Commission pursuant to a Current Report on Form 8-K.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Amendments;
                                            Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended
                                            except in a written instrument signed, in the case of an amendment, by the Company and Purchasers
                                            which purchased at least 50.1% in interest of the sum of the (x) Shares and (y) the Pre-Funded
                                            Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants based on the initial
                                            Subscription Amounts hereunder (or, prior to the Closing Date, the Company and each Purchaser)
                                            or, in the case of a waiver, by the party against whom enforcement of any such waived provision
                                            is sought, provided that if any amendment, modification or waiver disproportionately and
                                            adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately
                                            impacted Purchaser (or at least 50.1% in interest of such disproportionately impacted Purchasers)
                                            shall also be required. No waiver of any default with respect to any provision, condition
                                            or requirement of this Agreement shall be deemed to be a continuing waiver in the future
                                            or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
                                            hereof, nor shall any delay or omission of any party to exercise any right hereunder in any
                                            manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
                                            materially and adversely affects the rights and obligations of any Purchaser relative to
                                            the comparable rights and obligations of the other Purchasers shall require the prior written
                                            consent of such adversely affected Purchaser. Any amendment effected in accordance with this
                                            Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Headings</U>.
                                            The headings herein are for convenience only, do not constitute a part of this Agreement
                                            and shall not be deemed to limit or affect any of the provisions hereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Successors
                                            and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties
                                            and their successors and permitted assigns. The Company may not assign this Agreement or
                                            any rights or obligations hereunder without the prior written consent of each Purchaser (other
                                            than by merger). Any Purchaser may assign any or all of its rights under this Agreement to
                                            any Person to whom such Purchaser assigns or transfers any Securities, provided that such
                                            transferee agrees in writing to be bound, with respect to the transferred Securities, by
                                            the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
                                            Third-Party Beneficiaries</U>. The Placement Agent shall be the third-party beneficiary of
                                            the representations and warranties of the Company in Section 3.1 and the representations
                                            and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit
                                            of the parties hereto and their respective successors and permitted assigns and is not for
                                            the benefit of, nor may any provision hereof be enforced by, any other Person, except as
                                            otherwise set forth in Section 4.8 and this Section 5.8.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing
                                            Law</U>. All questions concerning the construction, validity, enforcement and interpretation
                                            of the Transaction Documents shall be governed by and construed and enforced in accordance
                                            with the internal laws of the State of New York, without regard to the principles of conflicts
                                            of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
                                            enforcement and defense of the transactions contemplated by this Agreement and any other
                                            Transaction Documents (whether brought against a party hereto or its respective affiliates,
                                            directors, officers, shareholders, partners, members, employees or agents) shall be commenced
                                            exclusively in the state and federal courts sitting in the City of New York. Each party hereby
                                            irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
                                            in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder
                                            or in connection herewith or with any transaction contemplated hereby or discussed herein
                                            (including with respect to the enforcement of any of the Transaction Documents), and hereby
                                            irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
                                            it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
                                            is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably
                                            waives personal service of process and consents to process being served in any such Action
                                            or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery
                                            (with evidence of delivery) to such party at the address in effect for notices to it under
                                            this Agreement and agrees that such service shall constitute good and sufficient service
                                            of process and notice thereof. Nothing contained herein shall be deemed to limit in any way
                                            any right to serve process in any other manner permitted by law. If any party shall commence
                                            an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in
                                            addition to the obligations of the Company under Section 4.8, the prevailing party in such
                                            Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
                                            fees and other costs and expenses incurred with the investigation, preparation and prosecution
                                            of such Action or Proceeding.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Survival</U>.
                                            The representations and warranties contained herein shall survive the Closing and the delivery
                                            of the Securities for the applicable statute of limitations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Execution</U>.
                                            This Agreement may be executed in two or more counterparts, all of which when taken together
                                            shall be considered one and the same agreement and shall become effective when counterparts
                                            have been signed by each party and delivered to each other party, it being understood that
                                            the parties need not sign the same counterpart. In the event that any signature is delivered
                                            by facsimile transmission or by e-mail delivery of a &ldquo;.pdf&rdquo; format data file,
                                            by other electronic signing created on an electronic platform (such as DocuSign) or by digital
                                            signing (such as Adobe Sign), such signature shall create a valid and binding obligation
                                            of the party executing (or on whose behalf such signature is executed) with the same force
                                            and effect as if such facsimile or &ldquo;.pdf&rdquo; or other electronic or digital signature
                                            page were an original thereof.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severability</U>.
                                            If any term, provision, covenant or restriction of this Agreement is held by a court of competent
                                            jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions,
                                            covenants and restrictions set forth herein shall remain in full force and effect and shall
                                            in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
                                            reasonable efforts to find and employ an alternative means to achieve the same or substantially
                                            the same result as that contemplated by such term, provision, covenant or restriction. It
                                            is hereby stipulated and declared to be the intention of the parties that they would have
                                            executed the remaining terms, provisions, covenants and restrictions without including any
                                            of such that may be hereafter declared invalid, illegal, void or unenforceable.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Rescission
                                            and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without
                                            limiting any similar provisions of) any of the other Transaction Documents, whenever any
                                            Purchaser exercises a right, election, demand or option under a Transaction Document and
                                            the Company does not timely perform its related obligations within the periods therein provided,
                                            then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon
                                            written notice to the Company, any relevant notice, demand or election in whole or in part
                                            without prejudice to its future actions and rights, unless such rescission or withdrawal
                                            would materially prejudice the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Replacement
                                            of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated,
                                            lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and
                                            substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
                                            and substitution therefor, a new certificate or instrument, but only upon receipt of evidence
                                            reasonably satisfactory to the Company of such loss, theft or destruction. The applicant
                                            for a new certificate or instrument under such circumstances shall also pay any reasonable
                                            third-party costs (including customary indemnity) associated with the issuance of such replacement
                                            Securities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Remedies</U>.
                                            In addition to being entitled to exercise all rights provided herein or granted by law, including
                                            recovery of damages, each of the Purchasers and the Company will be entitled to specific
                                            performance under the Transaction Documents. The parties agree that monetary damages may
                                            not be adequate compensation for any loss incurred by reason of any breach of obligations
                                            contained in the Transaction Documents and hereby agree to waive and not to assert in any
                                            Action for specific performance of any such obligation the defense that a remedy at law would
                                            be adequate.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Payment
                                            Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser
                                            pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder,
                                            and such payment or payments or the proceeds of such enforcement or exercise or any part
                                            thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
                                            recovered from, disgorged by or are required to be refunded, repaid or otherwise restored
                                            to the Company, a trustee, receiver or any other Person under any law (including, without
                                            limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
                                            then to the extent of any such restoration the obligation or part thereof originally intended
                                            to be satisfied shall be revived and continued in full force and effect as if such payment
                                            had not been made or such enforcement or setoff had not occurred.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Independent
                                            Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser
                                            under any Transaction Document are several and not joint with the obligations of any other
                                            Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
                                            of the obligations of any other Purchaser under any Transaction Document. Nothing contained
                                            herein or in any other Transaction Document, and no action taken by any Purchaser pursuant
                                            hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
                                            a joint venture or any other kind of entity, or create a presumption that the Purchasers
                                            are in any way acting in concert or as a group with respect to such obligations or the transactions
                                            contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
                                            protect and enforce its rights including, without limitation, the rights arising out of this
                                            Agreement or out of the other Transaction Documents, and it shall not be necessary for any
                                            other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each
                                            Purchaser has been represented by its own separate legal counsel in its review and negotiation
                                            of the Transaction Documents. For reasons of administrative convenience only, each Purchaser
                                            and its respective counsel have chosen to communicate with the Company through the legal
                                            counsel to the Placement Agent. The legal counsel of the Placement Agent does not represent
                                            any of the Purchasers and only represents the Placement Agent. The Company has elected to
                                            provide all Purchasers with the same terms and Transaction Documents for the convenience
                                            of the Company and not because it was required or requested to do so by any of the Purchasers.
                                            It is expressly understood and agreed that each provision contained in this Agreement and
                                            in each other Transaction Document is between the Company and a Purchaser, solely, and not
                                            between the Company and the Purchasers collectively and not between and among the Purchasers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liquidated
                                            Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other
                                            amounts owing under the Transaction Documents is a continuing obligation of the Company and
                                            shall not terminate until all unpaid partial liquidated damages and other amounts have been
                                            paid notwithstanding the fact that the instrument or security pursuant to which such partial
                                            liquidated damages or other amounts are due and payable shall have been canceled.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Saturdays,
                                            Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or
                                            the expiration of any right required or granted herein shall not be a Business Day, then
                                            such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Construction</U>.
                                            The parties agree that each of them and/or their respective counsel have reviewed and had
                                            an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction
                                            to the effect that any ambiguities are to be resolved against the drafting party shall not
                                            be employed in the interpretation of the Transaction Documents or any amendments thereto.
                                            In addition, each and every reference to share prices and shares of Common Stock in any Transaction
                                            Document shall be subject to adjustment for reverse and forward stock splits, stock dividends,
                                            stock combinations and other similar transactions of the Common Stock that occur after the
                                            date of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5.21</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>WAIVER
                                            OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY
                                            PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
                                            EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
                                            WAIVES FOREVER TRIAL BY JURY.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">IN
WITNESS WHEREOF</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the parties hereto have caused this
Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>OS
    Therapies Incorporated</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address
    for Notice:</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 34%">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    par@ostherapies.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Name:&nbsp;    </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Paul A. Romness, MPH</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">President and Chief Executive Officer</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Olshan
Frome Wolosky LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1325
Avenue of the Americas, 15<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn.:
Spencer G. Feldman, Esq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Remainder
of page intentionally left blank;<BR>
signature page for Purchaser follows.</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="text-transform: uppercase">PURCHASER
SIGNATURE PAGE TO OSTX SECURITIES PURCHASE AGREEMENT</FONT>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">IN
WITNESS WHEREOF</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the undersigned have caused this Securities
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Purchaser:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    of Authorized Signatory of Purchaser:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice to Purchaser:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
for Shares: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares:
_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Warrant Shares: ____________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<FONT STYLE="text-transform: uppercase">PURCHASER
SIGNATURE PAGE TO OSTX SECURITIES PURCHASE AGREEMENT</FONT>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">IN
WITNESS WHEREOF</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the undersigned have caused this Securities
Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Purchaser:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
    of Authorized Signatory of Purchaser:</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
    for Notice to Purchaser:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address
for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DWAC
for Shares: ____________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription
Amount: $_________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded
Warrant Shares: ____________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Warrant Shares: ______________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
A</B><BR>
<BR>
<B>Form of Lock-Up Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Lock-Up
Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________,
2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ceros
Financial Services, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1445
Research Boulevard</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rockville,
Maryland 20850</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:
OS Therapies Incorporated&mdash;Proposed Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that you (&ldquo;<B><I>Ceros</I></B>&rdquo; or the &ldquo;<B><I>Placement Agent</I></B>&rdquo;) propose to enter
into or have entered into a Placement Agency Agreement (the &ldquo;<B><I>Placement Agency Agreement</I></B>&rdquo;) providing for the
offer and sale (the &ldquo;<B><I>Offering</I></B>&rdquo;) of (i) shares of common stock, par value $0.001 per share (the &ldquo;<B><I>Common
Stock</I></B>&rdquo;), of OS Therapies Incorporated, a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and (ii)&nbsp;warrants
to purchase shares of Common Stock (the &ldquo;<B><I>Common Warrants</I></B>&rdquo; and, together with the Common Stock, the &ldquo;<B><I>Securities</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the execution of the Placement Agency Agreement by Ceros, and for other good and valuable consideration, the undersigned
hereby irrevocably agrees that, without the prior written consent of Ceros, the undersigned will not, directly or indirectly, (a) offer
for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction that is designed to, or could reasonably be
expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock (including,
without limitation, shares of Common Stock that may be deemed to be beneficially owned by the undersigned in accordance with the rules
and regulations of the Securities and Exchange Commission and shares of Common Stock that may be issued upon exercise of any options
or warrants) or securities convertible into or exercisable or exchangeable for Common Stock; (b) enter into any swap or other derivatives
transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of Common Stock,
whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Common Stock or other securities, in
cash or otherwise; (c)&nbsp;except as provided for below, make any demand for or exercise any right or cause to be filed a registration
statement, including any amendments thereto, with respect to the registration of any shares of Common Stock or securities convertible
into or exercisable or exchangeable for Common Stock or any other securities of the Company; or (d) publicly disclose the intention to
do any of the foregoing for a period commencing on the date hereof and ending on the earlier of (i) ninety (90) days following the closing
of the Offering, and (ii) the date on which the Company publicly announces that the U.S. Food and Drug Administration has accepted for
filing (i.e., accepted for substantive review) its Biologics License Application for OST-HER2 (such period, the &ldquo;<B>Lock-Up Period</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing paragraph shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in the open market
after the completion of the Offering, <I>provided that</I> no filing under Section 16(a) of the Securities Exchange Act of 1934, as amended
(the &ldquo;<B><I>Exchange Act</I></B>&rdquo;), shall be required or shall be voluntarily made in connection with such transactions;
(b)&nbsp;bona fide gifts of shares of Common Stock or any security convertible into Common Stock, in each case that are made exclusively
between and among the undersigned or members of the undersigned&rsquo;s family, or affiliates of the undersigned, including its partners
(if a partnership) or members (if a limited liability company); (c) any transfer of shares of Common Stock or any security convertible
into Common Stock by will or intestate succession upon the death of the undersigned; (d)&nbsp;transfer of shares of Common Stock or any
security convertible into Common Stock to an immediate family member (for purposes of this Lock-Up Letter Agreement, &ldquo;<B>immediate
family</B>&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin) or any trust, limited
partnership, limited liability company or other entity for the direct or indirect benefit of the undersigned or any immediate family
member of the undersigned; <I>provided </I>that, in the case of clauses (b), (c) and (d)&nbsp;above, it shall be a condition to any such
transfer that (i)&nbsp;the transferee/donee agrees to be bound by the terms of this Lock-Up Letter Agreement (including, without limitation,
the restrictions set forth in the preceding sentence) to the same extent as if the transferee/donee were a party hereto; (ii) each party
(donor, donee, transferor or transferee) shall not be required by law (including without limitation the disclosure requirements of the
Securities Act of 1933, as amended (the &ldquo;<B><I>Securities Act</I></B>&rdquo;), and the Exchange Act) to make, and shall agree to
not voluntarily make, any filing or public announcement of the transfer or disposition prior to the expiration of the Lock-Up Period;
and (iii)&nbsp;the undersigned notifies Ceros at least two (2) business days prior to the proposed transfer or disposition; (e) the transfer
of shares to the Company to satisfy withholding obligations for any equity award granted pursuant to the terms of the Company&rsquo;s
stock option/incentive plans, such as upon exercise, vesting, lapse of substantial risk of forfeiture, or other similar taxable event,
in each case on a &ldquo;cashless&rdquo; or &ldquo;net exercise&rdquo; basis (which, for the avoidance of doubt shall not include &ldquo;cashless&rdquo;
exercise programs involving a broker or other third party), <I>provided</I> that as a condition of any transfer pursuant to this clause
(e), that if the undersigned is required to file a report under Section 16(a) of the Exchange Act, reporting a reduction in beneficial
ownership of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock during the Lock-Up
Period, the undersigned shall include a statement in such report, and if applicable an appropriate disposition transaction code, to the
effect that such transfer is being made as a share delivery or forfeiture in connection with a net value exercise, or as a forfeiture
or sale of shares solely to cover required tax withholding, as the case may be; (f)&nbsp;transfers of shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock pursuant to a bona fide third party tender offer made to all holders
of the Common Stock, merger, consolidation or other similar transaction involving a change of control (as defined below) of the Company,
including voting in favor of any such transaction or taking any other action in connection with such transaction, <I>provided</I> that
in the event that such merger, tender offer or other transaction is not completed, the Common Stock and any security convertible into
or exercisable or exchangeable for Common Stock shall remain subject to the restrictions set forth herein; (g)&nbsp;the vesting of equity
awards, the exercise of warrants or the exercise of stock options granted pursuant to the Company&rsquo;s stock option/incentive plans
or otherwise outstanding on the date hereof; <I>provided</I>, that the restrictions shall apply to shares of Common Stock issued upon
such vesting, exercise or conversion; (h) the establishment of any, or the continued use of any existing, contract, instruction or plan
that satisfies all of the requirements of Rule 10b5-1 (a &ldquo;<B><I>Rule 10b5-1 Plan</I></B>&rdquo;) under the Exchange Act; <I>provided</I>,
<I>however</I>, that except for already existing plans, no sales of Common Stock or securities convertible into, or exchangeable or exercisable
for, Common Stock, shall be made pursuant to a Rule 10b5-1 Plan prior to the expiration of the Lock-Up Period; <I>provided further</I>,
that the Company is not required to report the establishment of such Rule 10b5-1 Plan in any public report or filing with the Commission
under the Exchange Act during the Lock-Up Period and does not otherwise voluntarily effect any such public filing or report regarding
such Rule 10b5-1 Plan; and (i) any demands or requests for, exercise any right with respect to, or take any action in preparation of,
the registration by the Company under the Securities Act of the undersigned&rsquo;s shares of Common Stock, provided that no transfer
of the undersigned&rsquo;s shares of Common Stock registered pursuant to the exercise of any such right and no registration statement
shall be filed under the Securities Act with respect to any of the undersigned&rsquo;s shares of Common Stock during the Lock-Up Period.
For purposes of clause (f) above, &ldquo;<B>change of control</B>&rdquo; shall mean the consummation of any bona fide third party tender
offer, merger, purchase, consolidation or other similar transaction the result of which is that any &ldquo;<B>person</B>&rdquo; (as defined
in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the
Exchange Act) of a majority of total voting power of the voting stock of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar
against the transfer of the undersigned&rsquo;s securities subject to this Lock-Up Letter Agreement except in compliance with this Lock-Up
Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is understood that, if the Company notifies Ceros that it does not intend to proceed with the Offering, if the Placement Agency Agreement
does not become effective, or if the Placement Agency Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Shares, the undersigned will be released from its obligations under this Lock-Up
Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned understands that the Company and Ceros will proceed with the Offering in reliance on this Lock-Up Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Letter Agreement shall automatically terminate upon (a) the termination of the Placement Agency Agreement prior to the issuance
and delivery of the Securities, (b) the date that either the Company or Ceros provides written notice to the other that it has determined
not to proceed with the proposed Offering and, with respect to the Company, is terminating this Lock-Up Letter Agreement on behalf of
all of the Company&rsquo;s holders of securities subject to a Lock-Up Letter Agreement, provided that the Company and Ceros shall not
have executed the Placement Agency Agreement on or prior to such date. Notwithstanding anything herein to the contrary, this Lock-Up
Letter Agreement shall lapse and become null and void if the closing of the Offering shall not have occurred on or before April 17, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Lock-Up Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the
conflict of laws principles thereof. Delivery of a signed copy of this Lock-Up Letter Agreement by facsimile or e-mail/.pdf transmission
shall be effective as the delivery of the original hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Letter Agreement
and that, upon request, the undersigned will execute any additional documents necessary in connection with the enforcement hereof. Any
obligations of the undersigned shall be binding upon the heirs, personal representative, successors and assigns of the undersigned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to enforce the obligations of the undersigned under this Lock-Up Letter Agreement, the Company shall impose irrevocable stop-transfer
instructions preventing its transfer agent from effecting any actions in violation of this Lock-Up Letter Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned acknowledges that the execution, delivery and performance of this Lock-Up Letter Agreement is a material inducement to each
purchaser in the Offering to complete the transactions contemplated in connection with the Offering, and that the Company shall be entitled
to specific performance of the undersigned&rsquo;s obligations hereunder. The undersigned hereby represents that the undersigned has
received adequate consideration for executing, delivering and performing this Lock-Up Letter Agreement, and that the undersigned will
indirectly benefit from the closing of the transactions contemplated in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Signatory, in the case of entities &ndash; Please&nbsp;Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Signatory, in the case of entities &ndash; Please&nbsp;Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Common Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
C</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Pre-Funded Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 47; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>8
<FILENAME>ea028448801ex99-1.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY OS THERAPIES INCORPORATED ON APRIL 2, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>OS Therapies Completes
$5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Company expects approximately $2 million in non-dilutive VAT refunds from wholly owned U.K. subsidiary in 2Q-26</I></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Company expects to receive approximately $2 million in non-dilutive R&amp;D tax credits repayable to the company in cash from its
U.K. subsidiary in 2H-26</I></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Offering net proceeds, together with funds expected to be received via U.K. subsidiary, expected to provide cash runway into 2027</I></TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><I>Company expects to receive approvals in the U.S., U.K. and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected,
pulmonary metastatic osteosarcoma in the second half of 2026 </I></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>New York, NY,
April 2, 2026 &ndash; OS Therapies, Inc. (NYSE-A: OSTX) </B>(&ldquo;OS Therapies&rdquo; or &ldquo;the Company&rdquo;), the world
leader in gene-edited, listeria-based cancer immunotherapies, today announced it that it has completed a $5.25 million registered
direct offering of common stock (or pre-funded warrants in lieu thereof) and warrants, with participation primarily from
high-net-worth investors who have invested in several of the Company&rsquo;s prior financing rounds. Each investor was issued either
shares of common stock at a purchase price of $1.40 per share or, in lieu thereof, pre-funded warrants at a purchase price of $1.399
per pre-funded warrant, together with one warrant to purchase one share of common stock at an exercise price of $1.40 per share for
each share of common stock issued or issuable upon exercise of the pre-funded warrants. Additional details related to the offering
are included in the Company&rsquo;s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the
&ldquo;SEC&rdquo;) on April 2, 2026. Ceros Financial Services, Inc. acted as the exclusive placement agent for the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Additionally, the Company announced that it
expects to receive approximately $4 million in additional non-dilutive funds from VAT refunds and R&amp;D reclaim funds via its wholly
owned U.K. subsidiary that was established in 2025 for the purpose of conducting research &amp; development.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&ldquo;This capital raise, together with the
non-dilutive funding we expect to receive from our U.K. subsidiary, is expected to support our operations as we advance toward crucial
anticipated 2026 regulatory milestones for OST-HER2 in the U.S., U.K. and Europe, including early market access authorizations and potential
eligibility for a Priority Review Voucher (PRV) under our Rare Pediatric Disease Designation (RPDD),&rdquo; said Paul Romness, President
&amp; CEO of OS Therapies. &ldquo;We are now focused on our upcoming regulatory interactions, including planned meetings later this quarter
with the U.S. Food &amp; Drug Administration (FDA), the European Medicines Agency (EMA), the U.K. Medicines and Healthcare products Regulatory
Agency (MHRA) and the Australian Therapeutic Goods Administration (TGA) to review our clinical and biomarker data, as well as our proposed
confirmatory Phase 3 trial design. We are hopeful these interactions will support market access for osteosarcoma patients beginning in
2027. This funding is also expected to support the initiation of a Phase 3 confirmatory trial, including the planned activation of an
initial trial site in Australia, which is part of the requirements for a Biologics License Application (BLA) under the U.S. Accelerated
Approval Program (Accelerated Approval) and for Conditional Marketing Authorisations (CMAs) in the U.K. and Europe.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">OST-HER2 has received Orphan Drug Designation
(ODD), Fast Track Designation (FTD) and RPDD from the FDA, and ODD, FTD and ATMP from the EMA. Under the RPDD program, if the Company
receives a BLA in the United States, it will become eligible to receive a PRV that it intends to sell, subject to market conditions. The
most recent publicly disclosed PRV transaction occurred in February 2026 at a reported value of $205 million; however, there can be no
assurance that the Company would realize a comparable value, if any, in connection with any future PRV sale. The Company is seeking to
obtain a BLA under the Accelerated Approval Program for OST-HER2 in osteosarcoma in the second half of 2026.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The securities described above were offered
pursuant to a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-289443) filed by the Company with the SEC on August
8, 2025 and declared effective by the SEC on August 25, 2025. The offering was made only by means of a prospectus, including a prospectus
supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating
to the securities being offered were filed with the SEC and are available at the SEC&rsquo;s website at www.sec.gov. Electronic copies
of the prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting
Ceros Financial Services, Inc. at 1445 Research Boulevard, Rockville, Maryland 20850, or e-mail Ahmed Gheith, Managing Director at Ceros
at agheith@cerosfs.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>No Offer to Sell or Solicit</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release is for informational purposes
only and does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About OS Therapies</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">OS Therapies is a clinical stage oncology
company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors.
The Company is the world leader in listeria-based cancer immunotherapies. OST-HER2, the Company&rsquo;s lead asset, is an immunotherapy leveraging
the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received
Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food &amp; Drug
Administration and has received ODD, FTD and ATMP from the European Medicines Agency. The Company reported positive data in its Phase
2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit
in the 12-month event free survival (EFS) primary endpoint of the study and the overall survival (OS) secondary endpoint. The Company
anticipates receiving a Biologics License Application (BLA) from the U.S. FDA for OST-HER2 in osteosarcoma in 2026 and, if approved, would
become eligible to receive a Priority Review Voucher that it could then sell. The Company also anticipates receiving Conditional Marketing
Authorisations from the U.K.&rsquo;s Medicines and Healthcare products Regulatory Agency and the EMA for OST-HER2 in 2026. OST-HER2 has
completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models
of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
The Company also anticipates reading out data from a Phase 1b study of OST-504 in castration resistant prostate cancer in the first half
of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition, OS Therapies is advancing its
next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored
antibody-linker-payload candidates. This platform leverages the Company&rsquo;s proprietary silicone Si-Linker and Conditionally Active Payload
(CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Statements in this press release about future
expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking
statements within the meaning of the federal securities laws. These forward-looking statements and terms such as &ldquo;anticipate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should&rdquo; or other comparable terms involve risks
and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements
regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which
such statements are based. OS Therapies cautions readers that forward-looking statements are based on management&rsquo;s expectations
and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results
to differ materially, including, but not limited to our expected to provide cash runway into 2027, the intended use of net proceeds from
the offering, the potential approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in &ldquo;Risk Factors&rdquo;
in the Company&rsquo;s most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and
Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required
by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>OS Therapies Contact Information:<BR>
<BR>
</B>Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Harrison Seidner, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">WaterSeid Partners</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">OSTX@waterseid.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Public Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Stephanie Chen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Elev8 New Media</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">media@ostherapies.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">https://x.com/OSTherapies<BR>
https://www.instagram.com/ostherapies/<BR>
https://www.facebook.com/OSTherapies/<BR>
https://www.linkedin.com/company/os-therapies/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ea028448801_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028448801_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ? HH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^V_\ :D_:
ME^#W['OPBUGXS_&O7IM'\+Z9<0:7IFGZ=:_VCXC\6>);Z*XETOPKX6TH2P_V
MAK6HI:74RB>XM-.TZPM+[6-9U#3=&T[4-0MOS%T+_@H/_P %-/BAHD/Q.^#W
M_!*;5KOX0WD!U70YO'WQ^\%^#?'_ (F\.[/MEGJUCX2U^TT'7+5]7TMX+JPM
M[+P_XBMIY)E32-0\01F*6;B?^"A^E:7\5?\ @J]_P2_^"WQ+6*\^$44?Q!^(
M2:'J*HVAZ[XZTJTUK6M+LM1@F'V74Q-JO@/P;IC6%TL\<UGJ]YIOE&#6KJ*Y
M_?FOII1R_*<ORNK5RZCF>-S3#U,=.6,JXJ&%PN%6*K86C0H4L)6P\IXB;P]6
MK7K5:LO9<U*G3I?%*7Y)3K<2\:\3\7X/!<4X_A+(.#LSPO#U"CD>#R:MF^;Y
MQ/*,!G&.S',<9G6 S2&'RW#K,\)A,OR_!X.D\7[/&8G%8RSITJ7YZ?L2_P#!
M1/X;_MB:AXR^'%_X,\6_ K]H[X7JY^)W[/\ \1HY(O%&@0PW-O8W.K:)?RV&
MDGQ'H-K?W=I8WMS+I&B:SIMQ=Z>^KZ!IUGK&AW>J?H77X#?MYZ7I?PU_X*[_
M /!,+XI?#\PZ7\1_BI?>-OAQ\2H]-$$<WB'P'8/HN@V-UKMK&H-XR:/XZ\66
M<>H7L<LS6^@Z3'#,I\,Z<;+]^:Y,YPF$HK+<;@:<Z&&S7 O%QPE2I*K+"5J6
M)K8/$T85II3JX?VU'VF&G47M?93Y*CE*GSS]K@+.\YQTN*N'^(<3A\QS?@SB
M&.25<YPN&IX*GG6"QF4X#.\JQ]?!493P^#S)8+'+#9KA\)+ZHL;AW6PT*-+$
M_5Z)7BG[2/Q??]G_ . 7Q@^-T?AU?%TGPJ^'OB?QTGAA]7.@)KS>'=+N-1&E
MMK2Z9K1TM;PP>2;T:3J)MPWF?9)L;#[77Q;_ ,%&_P#DPS]KS_LW_P")G_J,
MW]>?E]*%?'X&C5CS4JV-P=*I&[7-3JXK#TZD;Q:DN:%2:NFFKW332:^EXGQF
M(R_AKB/,,'4]CB\!P_GF.PE7EA/V6*P>3YIBL-5Y*D94Y^SKX:C/DJ1E"7)R
MSC*,I)^A_LA_'B\_:>_9J^#WQ^O_  O;>"[OXI>$XO$\WA6TUB77[;1&FOKV
MU6RBUF;3='EU$(EJKM<-IED6=V40@*"?H^OSS_X)/?\ *.;]DC_LE-E_Z=]7
MK]#*O,Z-/#YEF%"C'DI4,=C*-*%V^6G2Q-:G"-Y-R?+"$5=MMVNVVVS+A'&X
MK,N%.&,QQM5U\;F'#N1X[%UG&$'6Q6+RK 8G$57"G&%.#J5JU2?+"$81YN6,
M8Q22*:[I&CR2.L<<:L[N[!41%!9G=F(55502S$@  DD 4ZJU[9VVH6=WI]Y$
M)[.^MI[.[@8LJS6US$\,\3,C*ZB2)W0E&5@#E6!P1Q*UU>]KJ]M[75[>=KV\
M['T$K\LN5)RL^52;47*SY5)I-J+ERIM)M)MI-I)_AE9_\%6_VHOCGJ'Q#\:_
ML/\ [ .O_M%_LY_"WQ+J/AW4_BEJGQ2T7P%K7Q ET:"*[U,_#_P7J6E2Z[>2
M26CK=:98:/8^-/$,ME?Z/+JGAS2-7U&+P]7ZI_LM?M 6?[4'P+\"?&ZR\ ^.
MOAE%XSL;B:7P;\1-)?2/$.E7EA=SZ=?B-75!J>BS7MK/+H.NQPVJ:UI36NH?
M8K%YWLX/PV^'W@#_ (*(?\$=M&\<^&OAA\)?#G[:'[%-GXIUGQ[91^']3;P]
M\9_ FDWZPG5I;G38(+[49YX;"RAFUE=)\-^-]&FN+.37H)?"<&H:E86W[>_L
MG_M2_"_]L;X)>&/CI\)KG4/^$=U^2]T[4=&UJ""U\0^%/$NDR+!K7ACQ!;6U
MQ=VL6I:=*\4BRVEU=66H:?=6.J6%S/8WUO*_UW$&"P5+#*OE6 P<\L6(HTL+
MF^#Q^(Q%>4)8=2>'S;"U:C^KXVK-5*JYL/A8QY)TJ#KP2<?Q#PSS[/\ &9M+
M+>,N),\P_%TLLQV*SC@?/.',KRS+Z=:EF<J<<TX)S?!8>']I\/X/#SP^$FZ6
M99Q4K+$8?%Y@L!B')5/H^BBBOD#]P/@O2_VT[W4_^"BGB']A%?AO:V]AX=_9
M]'QOE^*#>+99KR^N)M:\,Z5%X;C\&CPU##9PQIK\DTFJMXHNWE:V15T^$2,4
M]+_;:_:5F_8__9>^*G[1MMX+B^(<_P -K3PQ<1>#YO$3^$XM8;Q)XW\->#0)
M-?30_$CV"V/_  D7]IG;HMX;O[%]B!MOM/VRW_$;X]^//VB?AS_P7 ^(?B']
MF'X&Z3^T)\2W_8T\.Z9<^ ]9\=:-\/+2U\)7.O\ A6YU?Q.FO:[=V=C+<:;J
M5EH>G1Z4)3<7::S+-"A^R,R\U_P4A_:'_P""EOCG]BCXY^%OC[^P1X1^#7PE
MU33_  6/%WQ*T[X]^"/&%[X9CM/B7X,O='D@\-:5J]SJ.JMJ?B"VTG1G2UAD
M:VBU&2^E @M967[JAPW2Q&/X<</[/A@\9A,DJXVA6S7#4,57EB)S^N.&&JXB
M.+;K125*-&*YVK4%<_G+,/%C&9;PYXJ0KKB>MGN19SX@8/(<RP'!N;9AE&7T
M<LH4/[$A6S;"9;5R51P%24IXNICJD_8Q?-F$G$_H\^"_CZ?XK?![X4?%&ZTN
M'0[GXD?#;P/X\N-%M[Q]1@TB?Q?X9TSQ!+ID-_);64E[%8/J#6L=V]G:O<)$
M)FMX2YC7TNOG3]C[_DTK]E[/7_AGCX+9_P##;^&Z^BZ^,Q4(T\5BJ<%RPIXG
M$TX1U?+"&(KPA&[;;M&$5=MO35MW;_>\FKU<5D^3XFO-U*^)RG*L37J-13J5
M\1E>6XBM4:BHQ3G6KU9M1C&*<VHQC%12*\^^*_Q/\'?!7X:>._BW\0=3&D>"
MOAUX6UGQ?XEU )YLL.E:)92WMQ':6^Y&N[^Z\I;33K*-A+>W\]O:0YEF0'T&
MOYQ_^"V/[6'PJO?B+\ ?V%O'?Q&?P+\*/%/BOP_\3_VN_$>G6NMZI>Z9\,_#
M^HVVM>#/ <&G>%K75-<N]6\8ZAI=]K @@L ^C7VG^!-9G9M,O;J>S[\CRNIF
M^98?!QC5E3?/7Q4J,)5*D,)AXNMB94X13<JLJ</94(I7GB*]&*3NT?-^(?&&
M&X'X3S//JU7!T\5%4<ORBGCL13PV%Q&=YI5C@<KI8BM5E"%/"4\376-Q]5M1
MHY;E^/K2<5%-_L9^Q3^U7X5_;/\ V<? 'Q\\,646AS>);:[T_P 6^$5U$:K<
M>"?&^B7+6'B3PO=WIM+"2Y^QW2)=Z==RV-FVI:)?Z5JL=ND%_#GZLK^5_P#X
M)U_MD?LU?";_ (*0_%?X%?L[_$"QU?\ 9(_:[O+/QA\,M.?P[XA\&6?PQ^/,
MEHWF>![/2O%.FZ++::;XCBL]3T+2A86;Z?<F;X9^'M/E%U8W<)_J@KHXCRIY
M3F,J<*->AA,72IX[ T\3"4*U+#8A<WU:LI*ZK8.K[7"U4VVW2ISNU5BY>;X5
M\9QXUX5IXFOC\NS'.LDQN*X=XAQ655Z6(P&+S7*Y*E_:F!J47R2P&>8-X/.<
M$U&$5#&8F@HQE@ZD*91117@GZ0?$O[$G[<WPM_;7\$^(M3\)O%X=^(OPZ\0:
MAX2^*GPRO+]+O5_"FLV%_>6-OJEE,T%G)K7@[Q&ME-=^'/$<-G#!<&.]TF]B
ML]=TC5M.M,/]M']M2_\ V3?&W[*'@RP^&UIX\?\ ::^-NE?".;5+OQ?-X:7P
M3;WVI>';.;7H["'PSKQ\1S+#KDCQ:<U[H2"2U0/>NLY\K^;/]B7]F/\ :#D^
M&'QF_;Y_8RU_41^TQ\ ?VO/C3X,UOX6RF>^\/?'7X(V?A[X9>,=8^';Z+&R?
MVAK4FH:[K-S;Z4C1WFO^;9?\(_=Z5XWT#P?J47U/^U;^VG\,/VX[S_@E%\3/
M )?0O$NB?MK>&- ^*OPQU6ZCD\4_##QJ-8\#?:=#UB$Q6L]UI=X]K=W'AOQ"
M+*UMM<L(95DM].UJPUO1-)_1:O"^!AGLEA;XS*:<\90QE"4JD:V6XV&4XK&4
M:-?EDJCPM2HJ=3 XKFY*RIRPU:2KTW&M_*^%\8N(Z_AO2J9RH9#QKBJ&09AD
M.94Z>'J8#BO(<1QKE&18['Y:JU&6%AF^$PD\7AN(,FY/K&!GB:.:X&G/ 8J%
M; _U-T445^=']4!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7G_Q(\8ZGX'T*RUG3= 77O/\ $GA?1;X2ZG#I=OI=AX@\0:;H<VK2N\5S
M<WCVAU!&MM/L[5Y+VY,4,UQ86S37T'H%8OB#P_I?B?3'T?68'N;![S2K]HH[
MBXM7-UHNJV6M:>_G6LD,P6+4=/M9702!)D1H9E>&21&J+BI1<E>-]5W6M]FO
MS6Q,DW&2B[2:T>FCT[IK\'N>.>./BKXK\$^,Y-$'AC3_ !%8WWAGQ3K?A[2]
M*/B.W\07\OACPO?:^(CJMUH3>%[[4-8U+3YM"M_"6C7=_P")[2VDM_$Z6VI:
M8FJV^D<G/\;/'R^';^_T_P -Z#XADT;QM;>'=6\4>&]/\:Z[X5@T6;P1/XMO
M]832=(TG4/%$DOAW4C9>$]:@MH;Q8M3F8L;;4X[WP]IGM5U\,_#%[XE;Q7=/
MXCFU027ES:1/XP\5'2=)U'4-#F\-7>KZ)HG]L?V3HNK2:'<W.GI?Z9:6L]LE
MW?7%HT%YJ%_<W.!9? [P)IGAJV\(:7+XWTW0+2XFGAL[3XF_$5)0EW;2VM]9
MO?OXHDU"2QU".XN)KVUDNF2?49Y=7.-7;[<-HRH)1O"\ERW?*[.W-S;3_P *
MVM)ZNR5C&4*[<K3LGS<J4E=7Y>7>#ZJ7G%:*[=R?X@?%72/ WPY@\=)/HVKM
MJ\.C0>%8)-<LM#TCQ)J_B".-](@@US4V%G8Z?<Q/)J,E_<DI;Z5;W%TP?RMI
M\XOOVB4DCD_X1S2;'69-:TWPMXQ\"R/?FW@UKX=ZOX4U?Q/K>OW^!))9W6AM
MX1\4Z-<01B2*WU6Z\)VMZ\$FMQHWNJ^"_#*7?A6[CTN.,^"-/O-,\+6L<MQ'
MIVCVM[8VNERFVTQ918&ZATNT&EV5[+;R7=AIUWJ5E9306VJ:C'<XL'PI\ 6S
MW4L7AZ'S;JU\<V!D>[U"22UT[XDZE9:SXVTW3G>[9M-T_7=6TZUU&:RL#;V]
MK=H\UA':M/-YDQE12]Z$I.[=[K57]U6NMDDV_M<S2M9,J4:S?NSC&-DK6;=[
M:RNT]VVDOLI*3O=H\>T?]H2\MM)\#:UXKT:TGT?Q=<ZX=4UGPY9^)K*W\&:3
MI&C:1J+:UK&F>+-)TK6+W2;:\U$VFK:IIMK+::?8RPZ[)_Q*K+5[BQN6_P >
M=3N] \<:W#X?TS'A;PGH7B.RC34Y[B"_?6/B-\3O!!C>YCME7[*MEX"L]4@G
M@5O-DU*>$'R88II/5=#^%WA'P_)HTMFFOWC^'DU&'1SX@\7^+/%)L;?5-.L]
M*O+2)O$FM:JWV-[*QMXTM"QMHI!+/'$L\\TCX9^!/PRC;2UL]$O=*L-*M].L
MDT71_$/B'2?#]]INC>(]1\6:/I.KZ%8ZG!I6JZ1I6OZOJ=Y8Z9?6LUE%!?7.
ME&%]'FDT]JYL/=^Y):WND[6YKVY>;3W?=O=K6[U6L\N(LO?B]-4WK?E2OS<M
MFN:\K-7TLFT]*OPE^)&L_$.;Q5-J%KH]G9:+JVHZ9:VUA9^*8[V+[!X@U_1T
M:\O]9TFPT;5#<0Z,)VD\.W5_!:S/)!.X#6\DN#IGQ7\;3Z3X1\>ZEX:\.P?#
MWQ[?:+9:-;6FL7DWBW1+?Q:\5KX*UC6/,M4TG4DUZ_O-*M]7TC3?LUQX5CU0
M3_VAXABTZ]<>I>%/ 'AWP7+?R>'VU^*'4)KRXDL-0\7>*M=TFVFO]1NM6O'T
MO2-<UG4=-TCS[Z]N)F&F6MHH200*%MTCB7"L?@WX"T[4;:_M;'51#IU[?ZEH
MNA3>)O$=SX5T#4M3BO8;V_T#PM<:K+H&D7+1ZC>K:?8M/BBTD7-P='BT\W$Y
MDERH\TFHOE=N5<NMN5II>^N67-9\_O*R:Y=1\M;EBN9.2YN9\R5WS)IOW'S1
MY;KE7*[M.^FG+?#OXD^,O'OPJN_'4%GX4AUB;3K74=*L&A\8Z?IEN9-'T_5[
MJRU.76-&L=0O#;QWCQ0ZGHUM<Z7>D1O;SL!,J<5_PT==Z'X>O=0\8Z5I]MJT
MGP9T#XJZ):^']/\ &&MV%W<^(AXUN+?1=0O+'0KP:7!96OAS2DN=1OS:I//?
MWTEO&;>R<I])Z;X>T?1?#6G^$K&%K?0=+T2S\-6-J]U<2R1:5:6,6E6EL;R>
M5[N65;5(H1<2SO<ROB1Y7E8L>=A^&/@V#3=1TF+3KA;'5/ &C?#&]B_M75&:
M3P;H$&NVVEZ<LS7AEBN((?$FKJ^JQNNJ3FX1I[R1K>W,8ITN:5Z?NN;<4M&H
MW5E>[Z)W5G>^_5#A6M&U3WE"TF]4YVE=VMW:L[JUKV>SXCX;_%'7O'/C+Q9H
M=U9:'8Z;X;GGL_)M[;Q2^J22Q6NB3I<OJMUI,/A6>*9]2F4V-AJESJ%O&EN\
MT8;[2L-A/CKX3_X6OKGPOEN+".71M"N;TZJNLV$DLNOZ/8V^N^)/#DNBHYU*
MU;2O"^K:#K<&JR1M8:B9M=TV!TOO#>HQ5V7A[X;^%_"NL7^MZ&-?M+C4YIKF
M]L9/%_BV]T"2ZN+>SM9KM/#-]K=SX>M[IX;&V4W%OID4JNLLJNLMQ</+2U'X
M3^ ]3\-)X2O=+N#I(UC4==1XM9UFUU=M:U>?5+O5]0.O6]_%K3W6I_VSK$-^
MQOB+JPU"\L)5:QE:"ANBY/W9*+C%))6<79<TW>3YFK:*Z4N9W:L@4:ZBO>BY
M*<I2YG=2C=\L%:*Y4T]79M.*LG=GD$W[3NFMX9\/ZK:>&[M=;UOX:^.O&=[H
M][-)%'X:\0^#=!O=8A\)ZU<);,T<NO2:%XK&D7?EQ&^T[PSJ.IVT$D.U:J7G
MQ_\ %&ECX?B72O"FKR^,V\1R0V=FOCC0M0U<Z/K7@K1;70_#&G>(?#5OJ,WB
M"Y/BC4=24ZI9VFDS66BL[7UG927FJ:=[%JGP8^&NL1ZC'>>&HE_M>ZBO-5FL
M[_5-.NK^6#P3?_#F);B\L+VWNC#'X-U34-%6WCFCA5+N>[5!?2O=-'-\&? =
M[9Q6E_%XDU>.&RNK*TNM8\<^--9U&RAN]7\*Z^LNG:OJ>OW>J6%S9:UX+\-Z
MKI-W97D%QI-]IYN=-DMI;N\:XM3P_P#S[ENVT]=&I62?,MFUTNU%._,])<,3
M_P _([))I\NJ<;MKE>K2>NR<FK66O->$_B;XO\=ZK;Z9X?TCPW9QZ2&U/Q??
MZI>ZC,ITN?QMXP\+Z5IOAVTM(4DDU.]L?!NI:G>:IJ,T=AILLEC:06.K&ZNG
MTO-3]H*QU;6/BUX9\(Z/;>)_$OP^TG5]1\.Z-INN6EUJ/C";PU<MH?BNU?2[
M*&ZU319/#OBP1Z)+;W%I<7VKI<6UUH=IJ!N(H6[\?"+P7#-IMS80Z[HUYIIO
M42^T'Q7XFT2\OK._UV^\27&F:Q<:7JMJ^LZ8FM:GJ%Y966IFZBTLWU]%I@LX
M+Z]CN+4OPK\$2:-X8T*+3+NPLO!UG<V'AZ?2-;US1M7L;2\T.[\/WL)U_2M1
ML]<N!>V%V\UX]SJ,LMWJMO8ZW</)K&GV5[!/-1O\+MI96M9IW;D^:\U*W*DN
M5QC)V=TFWRU[)<ZO=MMM/F35DHKD2@XWYFWS*4HK11;2Y"#XW>%?#?PIN_BG
M\2?$WAW3O#VCWWV#6==T"P\67%G:S3ZQ;Z+90WWAR[T9O%>AZL;Z\M+/4="O
M;*[N=+N'W3W+0$R1Z/B?XQ:-X5\3^"]+O[.9_#'C'PYJNO-XR23R].\."TU/
MPIIFDR:_;31I<VFCZY=>*[2U.M8%OHEVMO\ VS%;6%Y+J%AUFE?#[PCIFA7W
MAMM+36]-U/4)-6UI/%$\_BJYUK59FMY#?ZS=>()=1GU"Y06EG':FY=X[*VLK
M&UL8[>UL[6&+0N_"?AO4-3M=7O--MKJX@\-ZQX1AAF)DTR7P[X@GTF[U;3)M
M*9CIMW!>-H6FAO/M962V@DMXF2WN;F.6;T;M\LVKSZI*SC'DLDKJ49<S;;<6
MN5.*U*M6LO>@G:'1MW4I<]VW:491Y4DDI)\S4G[M_FSPW\?/'/C$ZDOA_P +
M>'9-0L?A[X>\86?AN5O%DU_K&HZY\-M \=+I-OX@AT1/"U@KW^N)H%JNHZA%
MJ4@B_M-M/\ETB?7\'?M ZAXY\7R>&M!TC0[RVF\3:'9:9J$6I73S3^$;_P +
M3?$#4_%U[8BW\VPMK#P_J7A/PA%!,W[[XBWVL6#O'8Z5)7JOASX2>!O"&I6N
MH^&+36M$:SL-$TZ/2[#QAXOC\//9^'_#UEX3T1+KPP==;P_>-8Z#IEAI\,]W
MIDT[_8;>YEEDNX5G&MX?^''@;PIJ*ZOX=\-:=I.I)8:OI:7=HDBRIIVN^)K[
MQCJMBA:1E6UNO$VI7VKF%5"0W%S(L BAVQ+<IT/>Y:;UBN2^G*];\WO.ZV::
M]"(PK^[S5%I)\^M[QTMR^XK/=-.W1GE'B_XX:QX,\0Z[X:U#PB+N^T2+4O$\
M<MM=S0V6K_#\Z=%:>']1M;V>W^QV>O:A\0-0T[P/>Z;>7 CL8H;_ ,4NW]D^
M1&*_C'XL?$+X=0/;>+M#\#OJ&KZ4NJ^'M1TC5M=.AZ?+!XJ\'>'-8TOQ%'=:
M8-4EATFV\80:O:Z_IT,46LP:=?VL^C:#>-IT6H^TWG@?POJ-YXHOM2TM-1E\
M9:%I_ACQ%%?SW5Y9W^@:8-8%II2V,\SVEI:AM?U>29+.&W-U->R37+2R+$R<
MI;?!CP% [R7$/B#5[SR]'AM[_P 0^,_%GB'4].T[0_$&E>)].TS3+_6=:O;S
M3M._MS0])O=0BM)8FUI].LTUJ74$M;=8E&=%6O#9+F5F^9V5VGSKE2DM5:7,
MG;395*%:[M/=OEU2Y5=V37(^9N-K.\>5J^O7RO0_V@_$'B'6_"WA2Q\+:5'X
MA\9Z-I.K^'YWU#4?[!O=)/BKQYIVL^+H+Z[T_3IY_#MUX/\ !EKXN\'V"P1Z
M[X@3Q#80+;1:5::KKUA[=\2_&EQ\/_"<GB:UT"]\43Q:]X-T9="TV>W@U*^'
MBKQCH/A5SIQNWBMIKZT36FO;6RFFMUU&>V2P%S;-<K<1XT'P5^&UN7:VT*:$
M&ZTF^M/L^MZ["-)FT/Q7KWC31SH)AU)&T&"PUOQ-KBVMMH[65K%HNH3>&DA'
MAW;I8W;/P/:OX9LO#WB34;[Q));^(K/Q;<:C<W-W:S7&OZ=XRB\>:=+$L=Y)
M+:Z;INO6UHMAHZW,EC;Z59V^CF.33T,#*4J+E%QBU%/WHN]Y7;;U4G9)<JMH
M[W:;NK$5649J4DY-/EFFK1:2M=<JN[W=W=6LFE9M^%ZE^T9/?ZW9Z=X,M_#U
MYI.I>)KC1=-U_4(?%^HI>6UOX(^'_BDB71_#N@WNK:7J0O\ QK=:3>PZG!;0
M:,^BRIJ\EI?RO90UM:_:/UGPWXEN?#>J^&=)>]TR;X@6NI65MJLZ:G+?^$8A
MJ/A?3=)LY86-_??$S1_%/PXN?#<4;$6D]YXN@NOM+:" _L^I?!WP!J.ISZRF
MF:GHFK76L:GK]UJ/A/Q1XI\'7=UK&LZ9H^CZM?7,WA?6=(:>34K#0-'CO5EW
MQ7$]C'>RQM>O-<2:^H_#CP-J>M#Q)J?AS3[O7$F\*79U6Y$KW7VKP+<ZS>^%
M;QY6E^:ZT:?7]7>&Z<&>5+QH;J2>"*".*^?#Z?NY-<K33^+FTLW)2LTU?9*S
MU2ULI<,1K^\BGS)I_9Y=;JW+=-:6NW=:-]3A_'OQ)\6_#^R\-O?>%['5KWQ1
MI"Z'IXTV[O/L4?Q=O381>'O"]W*;:>:V\->(KBXU&.'Q%+&B:4=(V7ZE]4M/
M+S8_BGXR_L^+QY)H7AD_#:7Q7%X8,::GJ:^,5T^3Q<O@H>,?)^Q2Z4T+:H1?
MCPBI.J+H3K<'6&UY&\,M[-JGAS2=9U'P]JFI6\MQ=^%M2N=7T3_2[N*VMM2N
MM*O]$>\FLX9X[2]FCTW5-0M[8WT-P+1KJ2XMA%<A)5XY?A%X%76EUI++50(O
M$'_"5QZ"OB;Q&/!\7BH7?]H_\) G@X:K_P (TFJ#4R=8WC3! ->=O$/D?VZQ
MU(PI4N5*4/>UNTFT]9:)<RY79Q][6S7POK<HU>9\L_=TY4VDUI'5^X^974KP
MT;3^)?9^>]-_:LOH]"_X2/7_  UI3:/!KVBZ9J%_X;OM4U&*QGUGP[XVUU_"
M4XO=.L88_&>D)X<\.W&IL]V- M='\:Z3K&I7VDZ=&;N;WSQ7XS\8>#/A'K7C
MK4O"FG:GXNT#PI?>(]4\+:=KJVNDV\]C93:E>V7_  D%Y;222VNF6\4D=Q?V
M^F37%\UN\MEI8,\5NC+'X(?#33I=-DMO#\FW2[;2;2&VGUC6KJPNHM$TSQ+H
MNGOJFG7.H2V&K7"Z1XMUO2KFZU*VNKF_TR6RT^^EN;+2=*@LNH'@3PV/ DWP
MW-M>/X2G\-77A![*?5M5NKS_ (1^\T^72I;(:Q=7DVK[EL)FMH+EKXW4""/R
M9D:.,JYRH-Q<(-+G3DFMX)JZ7OZ:7O;>ZUC9WF$*ZC)3J)MP:@TUI.SLW[FN
MMK76EGI*ZMYGXJ^+FLZ!KNJO;:/I,_A#P;<^ ;+QG=W-W?1Z[+/\0;^VL;>?
MP_:P6LUHT'AR&_T[4KZ*\DDFUJ*YNK*Q-A=6$;ZACZ;\:/&/_"/:WJ^I^"](
MO-0;X9:=\7/"^DZ1X@DMHV\/ZF;S?H7B'4]0L7C@U+0X(+2[U#6-,M+JWU%+
MZ>WTO1'ETQ7U/U75?AGX.UGQ%8^);^RO6U*S_L9VMX-;UFSTG5)/#-Y)J'AR
MYUW0K6_ATG7;CP]?W#WFDW&JV5W+9W)MY0Y>TL3;T=%^$O@3P_8>(-.T^RO_
M +'KVA)X5OEO_$.NZHVG^%H(+]+3PUHLVI:E=2>']#T^+5KYK#3=*>SM[-;E
M?)58[>T6 4J/*DX-R7+?1ZV<;J_/Y2;:2NI1A9./,-QK<S?/:+<K:K325G9P
M\XI*^CBYMM2Y3S'Q+\>M2T'6_#=HVD:);6.IZ=\-[L66J7VHP:]XQN?B-K*:
M(]G\/XX+*6SO)/"$TMM=ZO'=M/-="\AMKJ/P]:M;ZS>_3=<K)X-\.2R^$GGM
M)9O^$)#'PS!-J&H/:V4XTW^R8[V6Q-U]DU'4;336GMK&_P!1@N[O3UN[V2RF
M@EO+B23JJSFX-1Y(\K2?-YZNW5]-_-V6B3=P4TY<\E)-KE7;1<W1==%Y*[U;
M2_-[_@H_^PQJW[8G@?X?^)OA9XRB^&/[3/[/_BI?'_P&^(<\UU;:?8ZVMQI=
MY?:!KMQ96FH7=II6JW>AZ)J-MJEKI^H76C:UHNFW8L;_ $V35M*U+Y4T3]NS
M_@JEX"T>#P)\4_\ @EOXD^)/Q1L81IB_$'X9_$_P]I_PT\37D2BU@UZ>&WT_
MQ99Z';W\R"]N[>3Q-:1Q)*Q%MI$6+>#]5OBK^T+X(^#^LZ;H?BBP\2W=YJFF
M'5K=]$L=.NK=;874UGMF>\U?3W6;S8'.U(I$V%3YF25'E_\ PV_\(_\ H#>/
MO_!/H7_S35]'@L3C7@:&%Q.34,WP5&52K@7B5B*=3#>VGS584<3A,50K/#5*
ML?:3PU53I>T4IP]G*<W+\GS_ "GAZGQ'F.<95Q]F' ^?8^GA<)Q##*Y99BL+
MFSP-%4<%7Q^5YUE&8X*&:X3!U5A:&:825'%_571H8A8JG0H1I_$?['O[&?[2
M_C_]J2[_ ."A'_!0";POIOQBL/#5QX2^!7P,\'7Z:KX>^"7AJ_MM1LKJ74-0
MM[K4M/GUU;#6=>MK.TL-:\0P>?XFU_7]3U5M6N]-TOPW^T5?'/\ PV_\(_\
MH#>/O_!/H7_S34?\-O\ PC_Z WC[_P $^A?_ #35S9C#.,RKQK5L#*G&E1IX
M;#8;#T8TL-A<-14O98?#T_;3<:<7*<FY3G4J5)U*M6<ZDY2/5X7Q' O">7UL
M#@.(:6*JXS'8K-<US3,\=4QF:YSFV-=-XO,\RQ7U&C&KB*JI4:4(4J-##87"
MT,/@\)AZ&&H4X'V-7RW^V[X"\7_%']D']I+X<_#_ $.;Q+XW\;?!OQWX:\*^
M'[>ZTZQGUC7=6T&[M-.T^*\U:\T_3+:2YN)$C6:^O;6V0MF69%!-<[_PV_\
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M_P#RP/\ 7#A;_H?9=_X-J?\ S*?8U%?'/_#;_P (_P#H#>/O_!/H7_S34?\
M#;_PC_Z WC[_ ,$^A?\ S34?V9F'_0'7_P# 8_\ RP/]<.%O^A]EW_@VI_\
M,I]C45\<_P##;_PC_P"@-X^_\$^A?_--1_PV_P#"/_H#>/O_  3Z%_\ --1_
M9F8?] =?_P !C_\ + _UPX6_Z'V7?^#:G_S*?8U%?'/_  V_\(_^@-X^_P#!
M/H7_ ,TU'_#;_P (_P#H#>/O_!/H7_S34?V9F'_0'7_\!C_\L#_7#A;_ *'V
M7?\ @VI_\RGV-17QS_PV_P#"/_H#>/O_  3Z%_\ --1_PV_\(_\ H#>/O_!/
MH7_S34?V9F'_ $!U_P#P&/\ \L#_ %PX6_Z'V7?^#:G_ ,RGV-17QS_PV_\
M"/\ Z WC[_P3Z%_\TU'_  V_\(_^@-X^_P#!/H7_ ,TU']F9A_T!U_\ P&/_
M ,L#_7#A;_H?9=_X-J?_ #*?8U%?'/\ PV_\(_\ H#>/O_!/H7_S34?\-O\
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MNM'@T33_ !=J]A?S:C!X!T[T[_AM_P"$?_0&\??^"?0O_FFH_P"&W_A'_P!
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95OJ\G+V3G!JFIWIT_C4)R7Q/1JZ2C%?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ea028448801_ex5-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028448801_ex5-1img2.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  7 HH# 2(  A$! Q$!_\0
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MW%UZC3E)WL[1\7_M/]KK_H2OV<?_  Z'Q-_^=#1_:?[77_0E?LX_^'0^)O\
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M_AQPO_SC/G'^T_VNO^A*_9Q_\.A\3?\ YT-']I_M=?\ 0E?LX_\ AT/B;_\
M.AKZ.HH^M1_Z \#_ ."*G_S8']CU/^AYQ#_X<<+_ /.,^<?[3_:Z_P"A*_9Q
M_P##H?$W_P"=#1_:?[77_0E?LX_^'0^)O_SH:^CJ*/K4?^@/ _\ @BI_\V!_
M8]3_ *'G$/\ X<<+_P#.,^<?[3_:Z_Z$K]G'_P .A\3?_G0T?VG^UU_T)7[.
M/_AT/B;_ /.AKZ.HH^M1_P"@/ _^"*G_ ,V!_8]3_H><0_\ AQPO_P XSYQ_
MM/\ :Z_Z$K]G'_PZ'Q-_^=#1_:?[77_0E?LX_P#AT/B;_P#.AKZ.HH^M1_Z
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M711]:7_0)@O_  1/_P":@_LB?_0YS_\ \.&'_P#G.?.G]H?M;?\ 0I?LZ?\
MAP_B7_\ .PH_M#]K;_H4OV=/_#A_$O\ ^=A7T711]:7_ $"8+_P1/_YJ#^R)
M_P#0YS__ ,.&'_\ G.?.G]H?M;?]"E^SI_X</XE__.PH_M#]K;_H4OV=/_#A
M_$O_ .=A7T711]:7_0)@O_!$_P#YJ#^R)_\ 0YS_ /\ #AA__G.?.G]H?M;?
M]"E^SI_X</XE_P#SL*/[0_:V_P"A2_9T_P##A_$O_P"=A7T711]:7_0)@O\
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MPWTC_:'[6W_0I?LZ?^'#^)?_ ,["C^T/VMO^A2_9T_\ #A_$O_YV%>!3?\%
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MVJH^S<'/6IF&2TIJ$^*,^3>)KX535;$3H^TPN(H8/%577I\+U*$<%AL=B:&
MKYE*K'+:6/J?4I8YXFG6AA_2X+_]J\SP"Z\*?L\K:F>$730?$'XDR3K;&11<
M-!')\,XXY)UAWM"DDD<;R!5>2-27'T-7RK9?MF? F_L/#]]#XDE\SQ)^T_XJ
M_9#T[3O*MWU!/C/X1\3>*_#M_I%[!%=R"TT^\MO"5UXGTJ^D?=>^&-6\/:B+
M=)-8MK>OJJN3%4Z\'#VV$CA;^T45&C.CSN#IJ?QU:G-R.I35U9+VBWYDSV\G
MQ.7XE8AX#.JN<J"PTJKJ8ZAC7AE7AB9X=+V.$POLOK$,-B9J,U.4UAINU/V<
MHOS_ ,3>"K[5-<LO%7AKQ)<>%?$MMI<^A7-T--M-:TS5]%FN5O8K/5-*NW@+
MS:;>B2[TF]L[VRGM)+N_AF^UVEY-;'9\(>%K7P?HB:1;7E[J<TE]JFKZGJVI
M&W.H:OK6N:C<ZMJ^IW8L[>TLXI+N_O)Y([6RM;:RLK?R;*RMX+2WAB0HKEN[
M6OI\NE[:[V5W97TN>SRJ][:_/K:^E[)NRNTM;&/IO@O4=*\;>(/%-GXHN5TK
MQ/>VFIZMX8?2M-D@DO[+PUIGAJ"6'5BG]HPQ+!I%G=- K%6N%D7<(I70['B[
M0M0\1Z-+I>FZV="FED0RSR:/I.OV-[:%9(KK3-4TG6+>:"[T^\BE83)!+970
MD2%DNQ$)H)RBB[NGU5K:+IMTU^8<JLUK9W;U?7>VNGR\^Y-X1\-VG@[PMX>\
M*6$]U=67AO1M.T2TN;YXWNY[?3;2*TBEN##'# LCI$&,=O#!;19$5O!# D<2
M<.OPBT%)+2Y651J-K\2+[XC'5!INGC49KB]U;4]5.C278B\\V$1U(VJ2>89C
M;01H< D HHYI)MW=WJ_/??\ \"?WBY8M)65EHO+;_)?<=GXP\-0^,/#U]X:N
MKRXL]/U9[*WU<6P7S-0T5+^UGUG0Y&8@QVGB'2XKO0M0EC*W$5AJ-R]J\5R(
M9H\KPO\ #[0?!>LZYJ'A>"+1-*U^UTO[9X:T^U@M=&36-,%U VOVT,*KY&H:
MCILNGZ9J 0"&>VT32V")-#*\Q11=VM?1[KH]M_N5NW2VMWRIM.VJV?5;[??J
MNO6]E9OB3X>:%XMUD:EKRF^LF\)ZOX4GTB10D$L.JZQH&M)J45W$T=Y9ZGIM
MYX?M)M,O+.6&YL;K9?VL\%Y;6\T>[X3\.VOA'PQX>\*V-Q=75EX<T;3=#L[F
M]9'O)[72[2*SMY;N2-(HY+EXH4:>1(XUDE+.(T#;0447;5KNRV73JOU!12;=
MM7N^NZ?YI'05S/C/PS;^,_"VN^%;JYDL[;7=/FTZ>YACCFDABGP'9(I@8I#M
M!7;("A!(8$<$HI)V=UNM5\AM733V:L_1F]:VEK8V\=K96UO9VL(*PVUK#';V
M\2LQ<B.&)4C0%V9B%4 LQ8\DFO-=/^%NG:7\0=3^(]CJ=U;ZWK6HWLFL(EK9
M>3J>A77AKP[HL'AZ[=HC.\&F:KX8L/$>E7RR+=V5S=ZS81G[#K%ZDA133:O9
M[JS\UOK\]1-)VNMG=>3\CI_&/A.W\7Z7;V3:A?:/J&FZI8:[H6MZ;]G:^T;6
MM+E,EI>PQ7D-S9W44D;SV-_8WEO+;7^F7E[92JHG\Q,[PKX,N]%U?6?$^O\
MB&X\4>)];L=+TB:_;3[32-/T_1-&FU*ZT_2M)TJT,WV:(WNKZE?7UU=WE_?W
MUS<(DMT+*QTVSLBBB[M:^GHNZ;UM>S:5U?6P<JO>VOJ^ETG:]FTFTG:ZN4O'
M7PSTOQ_<13:KJ.I6:VWAG7] LCIDB6MWIU[K6K^$];M?$FGWX5I[36]"O_"&
MGSZ3-'\D4DL[2*X(6MOPEX.TWP8FNVVD,T>F:MK4>K6>EK''%::)$F@:%HC:
M;IZQ@'[(\FBOJ9,I:076HW2[C&L>"BCF=N6[MVZ=PY8WYK:]^O8PY_A_<_\
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:/#0=.C4J>VK5>:JH2DI5=)U.:;G=SFY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ostx-20260331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaiC6aPtypR1WYkxs2tzHQnqTycj+0cCICr7bC6WUYUL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:OSTX="http://ostherapies.com/20260331" elementFormDefault="qualified" targetNamespace="http://ostherapies.com/20260331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://ostherapies.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ostx-20260331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ostx-20260331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ostx-20260331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ostx-20260331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="ostx-20260331.xsd#Cover" roleURI="http://ostherapies.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://ostherapies.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OS THERAPIES INCORPORATED<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001795091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-5118368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">115  Pullman Crossing Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Grasonville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">21638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">297-7793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OSTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0284488-8k_ostherapies.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ostherapies.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0284488-8k_ostherapies.htm">ea0284488-8k_ostherapies.htm</File>
    <File>ostx-20260331.xsd</File>
    <File>ostx-20260331_lab.xml</File>
    <File>ostx-20260331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>21
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0284488-8k_ostherapies.htm": {
   "nsprefix": "OSTX",
   "nsuri": "http://ostherapies.com/20260331",
   "dts": {
    "inline": {
     "local": [
      "ea0284488-8k_ostherapies.htm"
     ]
    },
    "schema": {
     "local": [
      "ostx-20260331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ostx-20260331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ostx-20260331_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://ostherapies.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0284488-8k_ostherapies.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0284488-8k_ostherapies.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ostherapies.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>22
<FILENAME>0001213900-26-039529-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-039529-xbrl.zip
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MN<-T%J#<V"%F,4S:U+8_<#D5CTN+7Q_ZMV+:J?INL;+8\NZ#"<G]K-:N&2\
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MXV V'.N2;!/[#X@Z/=_&Z: *I"Y+K.M)E$HVJ[[0L&YKL<KVK>99BOLJ]_#
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MBB'U- XJ*Y-Q8]\T+3B)_MB)T4 W8R<F0(M-?JS&I!NXV",>83WD1=I(!74
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MBR&EHH#K..7"(P_UHY?D21FZ$E*"5XF>:W8CA$!>_EI!:JUI_)(M>ZKA^1[
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MB;;7X<$M,2"2]H! I-FICJ16>S004F((V@J$]&0'D@5"*FF!,,]";%+L-@-
M2GV_?."C&7G2Y@ >9<S*$P0=S1Y!=0O D:IR:;F HV3K*Z/[A :2!ANE&.%.
M0*-4&]> C)+UTX+V>" CE@$RTAX<9,0BD!$+\$6TQRV.$[H6'Y3.&2P.'S1?
MN*_P02P&G?D=:%"*E?"0M-O"@M+<> TDB.6@@=@,$$B[$0C$8A@@ML( +>E
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M'O[<>COI?=4O-B:5[?V//P\[EO-*SLA&US&F^'/HC:R]_P=02P,$%     @
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MPIEQ@MZU&*SL]MNUUGKMZDOBHZ>%[#6!.F3B3R6>_%1.:SJ@3/[V5E?I^F?
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MI\_^%D<+W5QK743OSZ.+2UVI#;[L39&4U::L\'OQXT<J.M6YNE:5CLSOL[+
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MGLRQ1DO(6&0SAIFG7K:)/: 82RIO9($R_:IY:4RGMI 16>O*Y[J@]H/CBZ7
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M>@;WL>K$5]?+##1$ZEC[WK18]H()#Y22!T;O\%O?LP]_7OT9W03P^?L,\#$
MG[_/ )_].(&SI?M +-WJ(5BZ7D^/*<3#M@4FFPEGQJ\/0_WX"5QCD@7'TJP9
MN"/OX%E7?@K])F;D(CSUVMS &3Y*C1Q)'S\$YWO$U @<<%LSC1+ZAO<>>%V.
M,3 M^!LRMNSP8V<?4U6 6>##P*B11\M!_'"&CKG#KB>E\U6E3)P5L289?<W
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MI\QB[=/&<Z\\H0L,W!U37H]O39*J1<2VVJ(IU1FG99@6=[O$F!]N"+P3._'
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M5EJLY0=>OXO4> HZ;#"W:?/9 )P-P'TV ).'8 #^;-L*@RX.S>94T0DFLYB
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M50C+VY,!:ZNQMD\&K.TVW+[!J]X=KWH7RG>.=<?.*K"SPV_$#FP9CAL4OUT
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M;_%+/,:3_WIW=G)^_CIP86A+SZ-7;^%IL!ZT2S@DW+//(X4?_ND&9Z=,O06
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MA[@?ILPTL83#\QHY!BZ$RQF(:8;#$N1=L"\[,%'TWL\S<N'CMM4)<%$L,RA
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MV#*6"V=RT:92:P8_\9GU[A7-&GZ82Z*V<A6M+'*,H[R6[R /K-S$%7^=[HC
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M.W5J%#"Y?^JZ]PGEU15=-O.VE1GR>5!9EX;C^XXLOR_5D%E!/JJ&@]<U*S;
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MI9S)*H'M@/7[@3A!6W!\BWX,2*%NJ\7)%:;H'(9Q<($2G=-M,=<NSL2HP<A
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M$P7>,L?H\Q0DH6\VQQ;J+EB7N ^G C2(.5U<)V9];$U%JHDL"))1Y.!SV$?
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M*3K3Q=NK5R;M@LB#JBL!9+G:#NKV#&(_=-.*CQ^7-Z[*5$H.O7@)?B2.9K=
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MKR>L7"%RPYHQ:6+R/HJB%<SI<&0@?\Q06@?YSU'4MIIP!K9? =:OQ/,=))]
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MPY3>T.A4J_MRQ/1HN(O4I,"65)2P+,!;2/E5 <$ND2?)/,?()IZH;QZ23>L
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MA\I46EGIC&X%&E:7+!6IHQA)0QD6_(A,FHE94X+1<ET=9ZJ(:J<8Q%RBI+(
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M=Y$9C,E\=^VQ8<+H)6!KE4N)M:6W-((4:1E5Z<^Y9"DWP7;:IO4OA3 R+&W
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M9M=5V4J2;\)=RPC2GU3G)84O&2L/^6%.-0')<HJ5\29AV-:]I#)W^_L/H[?
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M$%7SNX8MWT,J,]8M9[5Q^2J%DZN,>W0)6@%ZIB6MG (IAU<*&DNB5_K?L1)
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MU_?/WAS_1B$\/YV]>GGP_P%02P,$%     @ (XN"7.WE2;D[2P  I/ ! !0
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MP)K1^C9_FR:+R(0/T<JM4GH%!H/):\+VSGAKY6S*LL)$%QW_,<^ A&!0U29
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M=3<6^]A>O:]6]?9X&Y61J,SCOVI49GO[KEOPL>3[@/8.M3[O]SX0CW>$7-,
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M%@>, ]X <JV\-.GH&,7 '2!T#=J>VW)=MC;OJOO'OIE#.+0S>*[?.TT^2?+
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M59<=>G?#=+D2PN_(+;@@W;USS9%!@7=I2  :+.M#3<?G92=FF&,:QF-B>'^
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MG[F)SP+@K-)GF>(UIL&R@P@JW),A,MG?G161+=8Q#0)K+A!S2H*2B?X.QJF
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MB8>BT>F3W 5&:<]"L,VRJDHORA%'>>?#:58K:Z7(T#ZSDJW^W%G =KPLV;B
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MV"B1AB@XUF,V1T1#6= 4F+H,WZG*:"QP!\*QTI2( $+B/!,$'2])* JKE#D
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MY>U%Z^+V46X,B7RFD(RK2T;;((\18[7\PL<=MP&+%EIU(?#6F;3--HYY;B^
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M?A@PC!2_2U4\3."6IJ#*3<\I]9$PO^*! QDO0D_0\S57X@L+U%D1U?JI/>+
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MMCSWAZDK7E==P.<NAKJ,%(H(=[+X.A9U,>8W)=45K$B%@5M#274A0NHT% <
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MS=W'C<[F$?6I_^YD0@./;]_)O(^[O;5A-^E_+_+_G1']KT?_!U!+ P04
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M97)A<&EE<RYH=&U02P$"% ,4    "  CBX)<("5.L-PL  #;40$ %
M        @ '/)@  96$P,C@T-#@X,#%E>#$M,2YH=&U02P$"% ,4    "  C
MBX)<&EEL( 3(  "H-@8 %0              @ '=4P  96$P,C@T-#@X,#%E
M>#$P+3$N:'1M4$L! A0#%     @ (XN"7!B++XT210  +GP! !0
M     ( !%!P! &5A,#(X-#0X.# Q97@T+3$N:'1M4$L! A0#%     @ (XN"
M7,?VYDV11P  ,(\! !0              ( !6&$! &5A,#(X-#0X.# Q97@T
M+3(N:'1M4$L! A0#%     @ (XN"7.WE2;D[2P  I/ ! !0
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3!@     +  L WP(  +(J @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>ea0284488-8k_ostherapies_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ostx-20260331.xsd" xlink:type="simple"/>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001795091</identifier>
        </entity>
        <period>
            <startDate>2026-03-31</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-03-31" id="Fact000004">0001795091</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-03-31" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-03-31" id="Fact000010">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-03-31" id="Fact000011">OS THERAPIES INCORPORATED</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-03-31" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-03-31" id="Fact000013">001-42195</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-03-31" id="Fact000014">82-5118368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-03-31" id="Fact000015">115  Pullman Crossing Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-03-31" id="Fact000016">Suite 103</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-03-31" id="Fact000017">Grasonville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-03-31" id="Fact000018">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-03-31" id="Fact000019">21638</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-03-31" id="Fact000020">410</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-03-31" id="Fact000021">297-7793</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-03-31" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-03-31" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-03-31" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-03-31" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2026-03-31" id="Fact000026">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2026-03-31" id="Fact000027">OSTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2026-03-31" id="Fact000028">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-03-31" id="Fact000029">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-03-31" id="Fact000030">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
